WO2007045593A2 - Naphthyl derivatives as inhibitors of beta-amyloid aggregation - Google Patents

Naphthyl derivatives as inhibitors of beta-amyloid aggregation Download PDF

Info

Publication number
WO2007045593A2
WO2007045593A2 PCT/EP2006/067323 EP2006067323W WO2007045593A2 WO 2007045593 A2 WO2007045593 A2 WO 2007045593A2 EP 2006067323 W EP2006067323 W EP 2006067323W WO 2007045593 A2 WO2007045593 A2 WO 2007045593A2
Authority
WO
WIPO (PCT)
Prior art keywords
methoxy
naphthyl
naphthalene
group
mmol
Prior art date
Application number
PCT/EP2006/067323
Other languages
French (fr)
Other versions
WO2007045593A3 (en
Inventor
Patrizia Minetti
Roberto Di Santo
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority to EA200801120A priority Critical patent/EA200801120A1/en
Priority to EP06841263A priority patent/EP1937243A2/en
Priority to AU2006303301A priority patent/AU2006303301A1/en
Priority to JP2008536020A priority patent/JP2009514810A/en
Priority to BRPI0617423-0A priority patent/BRPI0617423A2/en
Priority to US12/090,033 priority patent/US20080255232A1/en
Priority to CA002622545A priority patent/CA2622545A1/en
Publication of WO2007045593A2 publication Critical patent/WO2007045593A2/en
Publication of WO2007045593A3 publication Critical patent/WO2007045593A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/84—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/84—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • C07C215/86—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems being formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system

Definitions

  • the present invention relates to new compounds useful in the treatment of disorders characterised by deposits of amyloid aggregates, as well as to the pharmaceutical compounds containing the same together with pharmaceutically acceptable excipients.
  • amyloid deposits and changes in the neuronal cytoskeleton are among the clearest signs of Alzheimer's disease (AD). These two events, which involve mainly the cerebral cortex at an early stage, even if the final pathological picture of the disease involves the whole central nervous system, are a necessary, even if not a sufficient, condition for the onset of the disease (Chen M. (1998) Frontiers in Bioscience 3a, 32-37).
  • the amyloid substance has the characteristics of consisting of fibres 7-8 nm in diameter, of having an affinity for the Congo Red stain and of not being soluble in water.
  • AD amyloid fibres accumulate outside the cell, in the intracellular spaces of the brain and in the tunica media of the cortical and meningeal arterioles, producing three different macroscopic changes: senile plaques and diffuse plaques, which can be differentiated between in that there is the presence or absence of a change in the neuronal processes around the central amyloid deposit, and amyloid angiopathy, which is the expression of the infiltration of amyloid fibres in the wall of the arteries, between the smooth muscle fibres and the internal elastic lamina.
  • amyloid and helical filaments Apart from the formation of amyloid and helical filaments, a very serious synaptic rarefaction has been found in the cortex of subjects suffering from AD.
  • amyloid is the early and primary change in the disease and that the intraneuronal helical filaments are the intermediate expression of the damage to the neurons which, ultimately, lose the synaptic contacts, with the subsequent clinical effect of the deterioration in mental functions.
  • ⁇ Ai -42 The soluble form of a particular type of ⁇ -amyloid, ⁇ Ai -42 , hitherto considered to be toxic only in its aggregated form, is implicated in the progressive loss of memory and of the cognitive functions of Alzheimer's patients.
  • ⁇ Ai -42 produced in the initial stage of the disease, suppresses the activity of pyruvate dehydrogenase which promotes the synthesis of ACh providing for the transportation of acetyl-CoA, reducing the release of the neurotransmitter, changing the synaptic connections and causing the cholinergic deficits responsible for the disease (Hoshi M., Takashima A., Murayama M., Yasutake K., Yoshida N., lshiguro K., Hoshino T., lmahori K. (1997) The Journal of Biological Chemistry 272:4, 2038-2041).
  • This stain causes an increase in birefringence of the amyloid fibres and produces a characteristic circular dichroism indicative of a specific interaction between the stain and the substrate (the fibres) enabling diagnosis of amyloidosis in the tissue.
  • the protein ⁇ -amyloid ( ⁇ A) derives from the proteolytic action of a number of enzymes which act specifically on the precursor of the amyloid protein ( ⁇ APP) (Vassar R. et al. 1999 Science 286;735-740).
  • ⁇ -amyloid fragment can induce neurotoxic effects.
  • immunohistochemical studies have revealed the presence, in the senile plaques, of inflammation interleukins (IL-1 , IL-6), complement factors, other inflammatory factors and lysosomial hydrolases. It has been demonstrated that the ⁇ -amyloid protein is capable of stimulating the synthesis and secretion of IL-1 , IL-6 and IL-8 by the microglial cells and therefore of activating the cytotoxic mechanisms of acute inflammation (Sabbagh M. N.,
  • Diseases characterised by deposits of amyloid aggregates include, apart from Alzheimer's disease, Down's syndrome, hereditary cerebral haemorrhage associated with amyloidosis of the "Dutch type", amyloidosis accompanied by chronic inflammation, amyloidosis accompanied by multiple myeloma and other dyscrasias of the haematic "B" lymphoid cells, amyloidosis accompanied by type Il diabetes, amyloidosis accompanied by prion diseases such as Creutzfeldt-Jakob disease and Gerstmann-Straussler syndrome, kuru and ovine scrapie.
  • the reduction in the damage caused by ⁇ A can be dealt with by different therapeutic approaches: a) reducing the production of ⁇ A using inhibitors of the secretases to change the metabolism of the APP (increasing the ⁇ or reducing the ⁇ and ⁇ secretases); b) preventing or blocking the aggregation of the ⁇ A; c) increasing the clearance of the ⁇ A; d) blocking the neurotoxic effects of ⁇ A restoring calcium homeostasis; e) preventing the toxicity produced by the free radicals; f) preventing excitotoxicity; g) reducing the damage caused by the inflammatory response; h) correcting the imbalance between zinc and copper; i) inhibiting neuronal apoptosis
  • Alzheimer's disease are behavioural examinations and clinical "scores", while, due to an absence of suitable tracers, radiographic or scanning procedures are not yet able to accurately distinguish between degeneration of an Alzheimer's type and other degenerative phenomena.
  • the problems encountered in treating Alzheimer's disease, the severity of this disease and the difficulty of diagnosing it, make it desirable to not only find new drugs which are able to cure or slow down the progress of the disease but also discover compounds to be used in radiographic and scanning procedures capable of diagnosing it.
  • German patent DE 343057 claims the synthesis of 1-arylamino-4- oxynaphthalines.
  • One of the main objects of the present invention is the use of the compounds of Formula (I) as follows, for the preparation of pharmaceutical compounds useful in the treatment of conditions characterised by deposits of amyloid aggregates.
  • R is selected from the group consisting of H, OR 3 , COOR 3 , N(R 3 ) 2 , NO 2 , halogen, hydroxyalkyl Ci-C 3 ;
  • Ri and R 2 are the same or different and are selected from the group consisting of
  • R 3 is selected from the group consisting of H; Ci-C 4 linear or branched alkyl;
  • A is selected from the group consisting of NR 4 ; S; and SO 2 ;
  • R 4 is selected from the group consisting of H; Ci-C 4 linear or branched alkyl; Ci-
  • B is a phenyl or naphthyl group.
  • A is NH
  • Ri is N
  • R 2 is selected from the group consisting of H, COOH, COOCH 3 and OH; and R is selected from the group consisting of H, OH and OCH 3 .
  • Another object of the present invention are the compounds of general Formula (I)
  • R is selected from the group consisting of H, OR 3 , COOR 3 , N(R 3 ) 2 , NO 2 , halogen, hydroxyalkyl CrC 3 ;
  • Ri and R 2 are the same or different and are selected from the group consisting of
  • R 3 is selected from the group consisting of H; C 1 -C 4 linear or branched alkyl;
  • A is selected from the group consisting of NR 4 ; S; and SO 2 ;
  • R 4 is selected from the group consisting of H; Ci-C 4 linear or branched alkyl; Ci-
  • B is a phenyl or naphthyl group, with the proviso that: when A is NR 4 , Ri and R 2 are not both OR 3 ; and with the exception of the following compounds:
  • ST2763 Seki, Mieko; Yoneyama, Hiroto; Okuda, Daisuke; Hirose, Eiichi; Ozaki, Tadayoshi; Agata, Takashi; Ishii, Tom; Mashimo, Kiyokazu; Sato, Katsuhiro.
  • the present invention also comprises tautomers, geometrical isomers, optically active forms as enantiomers, diastereomers and racemate forms, as well as pharmaceutically acceptable salts of the compounds of Formula (I).
  • Preferred pharmaceutically acceptable salts of the Formula (I) are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, andpara-toluenesulfonate salts.
  • pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, andpara-toluenesulfonate salts.
  • A is NH
  • R is selected between OH and OCH 3 and/or is present on the naphthyl group in ortho position with respect to A
  • Ri is selected among OCH 3
  • COOCH 3 is selected among H
  • COOH and R 2 is selected among H, I, OH and OCH 3 .
  • examples of linear or branched C 1 -C 4 alkyl group are understood to include methyl, ethyl, propyl, butyl, and their possible isomers, such as, for example, isopropyl, isobutyl and ter-butyl.
  • Another object of the present invention is the use of the compounds of Formula (I) as medicines, or, in other words, as active principles of drugs, in particular for the treatment of diseases characterised by deposits of amyloid aggregates.
  • a further object of the present invention is the use of the compounds of Formula (I) referred to above or one of their pharmaceutically acceptable salts, for the preparation of pharmaceutical compositions useful in the treatment of disorders characterised by deposits of amyloid aggregates.
  • the compounds of Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used, unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures.
  • a further object of the present invention is a process for preparing general formula compounds (I). According to preferred embodiments of the invention some of such processes are reported in the section entitled Examples and are diagrammatically represented by some Schemes (see in particular Schemes 1 to
  • the compounds of Formula (I) may be obtained starting from a substituted or un-substituted nitro naphthalene.
  • the nitro naphthalene is hydrogenated with catalyst such as Pd/C in organic solvent such as ethyl acetate.
  • the amine so obtained is condensed with a substituted or un-substituted aryl halide derivative, with the reagent BINAP [2,2'-Bis(diphenylphosphino)-1 ,1'- binaphthyl] and Palladium acetate.
  • Next steps are deprotection of ether with BBr 3 and or hydrolysis of ester with NaOH.
  • a method of treating a mammal suffering from a pathology characterized by deposits of amyloid aggregates, comprising administering a therapeutically effective amount of a compound of Formula (I) as described above represents one of the aspects of the present invention.
  • therapeutically effective amount refers to an amount of a therapeutic agent needed to treat, ameliorate a targeted disease or condition, or to exhibit a detectable therapeutic effect.
  • the therapeutically effective dose can be estimated initially in in vitro assays, for example by measuring the residual aggregated beta- amyloid after incubation with the compounds of the invention; or in animal models, usually mice, rats, rabbits, dogs, pigs or monkeys, such as for example the amyloid precursor protein (APP)-transgenic mice.
  • in vitro assays for example by measuring the residual aggregated beta- amyloid after incubation with the compounds of the invention.
  • animal models usually mice, rats, rabbits, dogs, pigs or monkeys, such as for example the amyloid precursor protein (APP)-transgenic mice.
  • APP amyloid precursor protein
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • an effective dose will be from 0.01 mg/kg to 100 mg/kg, preferably 0.05 mg/kg to 50 mg/kg.
  • Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.
  • the medicament may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent.
  • Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
  • Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
  • compositions of therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient. Once formulated, the compositions of the invention can be administered directly to the subject.
  • the subjects to be treated can be animals; in particular, human subjects can be treated.
  • the medicament of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, rectal means or locally on the diseased tissue after surgical operation.
  • routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, rectal means or locally on the diseased tissue after surgical operation.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • a further object of the present invention are pharmaceutical compositions containing one or more of the compounds of formula (I) described earlier, in combination with excipients and/or pharmacologically acceptable diluents.
  • compositions in question may, together with the compounds of formula (I), contain other known active principles.
  • a further embodiment of the invention is a process for the preparation of pharmaceutical compositions characterised by mixing one or more compounds of formula (I) with suitable excipients, stabilizers and/or pharmaceutically acceptable diluents.
  • a further object of the present invention is the use of the compounds of
  • Formula (I) referred to above for the preparation of a diagnostic kit for diagnosing conditions characterised by deposits of amyloid aggregates.
  • the compounds according to the present invention may contain in their molecular structure atoms of elements commonly used in diagnostic imaging.
  • radioactive isotopes of carbon, hydrogen, nitrogen, oxygen, iodine and indium can be introduced into their structure.
  • the compound of formula (I) can have at least one of the elements carbon, hydrogen, nitrogen or oxygen of its own molecular structure replaced by a corresponding radioactive isotope; or carry at least one atom of radioactive iodine; or it is in the form of a complex with radioactive indium.
  • AFA (dimethylaminomethylphenylthio)]-5-fluorophenylamine was synthesized and evaluated as a candidate PET radioligand in pharmacological and pharmacokinetic studies.
  • AFA can be labeled with either C-
  • the compounds according to the present invention containing radioactive isotopes or atoms of elements useful as radio-opaque elements can be used as complexing agents for elements commonly used in diagnostic imaging techniques, such as gadolinium for example (NMR), technetium (scanning techniques).
  • R 3 OCH 3 1 NO 2
  • Reagents and conditions i) H 2 60 psi, 10% Pd/C ethyl acetate, rt 4h; ii) aryl halide Cs2CO 3 Pd(OAc) 2 ( ⁇ ) BINAP toluene, 80 0 C 19-39 h; iii) BBr 3 CH 2 Cl 2 -45°C 1-15 h then rt 4.5-15 h;CH 3 COCl,MeOH iv) BBr 3 CH 2 Cl 2 -45 0 C 15 h; v) IN NaOH, THF/ethanol 1 :1, reflux 3.5 h; Step i - Preparation of 4-methoxy-1-naphthalenamine
  • a suspension of 4-methoxy-1-nitronaphthalene (1.0 g, 4.9 mmol) in ethyl acetate (150 ml) was hydrogenated in Parr apparatus at room temperature in the presence of 10% Pd/C as a catalyst (200 mg) at an initial pressure of 60 psi for 4 h.
  • the catalyst was removed by filtration and the filtrate was dried and evaporated to afford pure 4-metossi-1-naphthalenamine (850 mg, 100% yield), which was used for the next reaction without further purification.
  • Step ii Preparation of 4-methylbenzoate-1-yl(4-methoxy-1-naphthyl)amine (ST3244)
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (70 mg,
  • 4-methoxy-3-methylbenzoate-1 -yl(4-methoxy-1 -naphthvDamine ST3245: Performed on 4-methoxy-1-naphthalenamine (1.6 g, 9.1 mmol), using ( ⁇ ) BINAP (470 mg, 0.76 mmol), palladium acetate (120 mg, 0.51 mmol) at 120 0 C.
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (50 mg, 0,08 mmol) and capped with a rubber septum.
  • the flask was purged with argon and dioxane (7,5 ml) was added.
  • the mixture was heated to 100 0 C with stirring until the BINAP dissolved.
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (13 mg, 0,055 mmol) was added.
  • the flask was recapped with the septum and then purged with argon.
  • Reagents and conditions i) H 2 60 psi, 10% Pd/C ethyl acetate, rt 4h; ii) Aryl halide , Cs 2 CO 3 Pd(OAc) 2 ( ⁇ ) BINAP toluene, 80 0 C; iii) BBr 3 CH 2 CI 2 -45°C 0.5h.; acetylchloride,methanol, 0°C,15 min (ST2762)
  • Step / - Preparation of 1-methoxy-2-naphthalenamine 1-Methoxy-2-naphthalenamine was obtained with the same procedure reported for 4-methoxy-1-naphthalenamine using 1-methoxy-2-nitronaphthalene (3.70 g, 18.0 mmol) as starting material. The 1-methoxy-2-naphthylenamine (3.12 g, 100 %) obtained was used for the next reaction without further purification.
  • Step H- Preparation of (1-methoxy-2-naphthyl)phenylamine ST2756).
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (70 mg, 0.11 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (9.7 ml) was added.
  • the mixture was heated to 80 0 C with stirring until the BINAP dissolved ( ⁇ 1 min).
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (16 mg, 0.07 mmol) was added.
  • the flask was recapped with the septum and then purged with argon (for ⁇ 30 sec).
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (210 mg, 0,34 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (31 ml) was added.
  • the mixture was heated to 80 0 C with stirring until the BINAP dissolved.
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (50 mg, 0,23 mmol) was added.
  • the flask was recapped with the septum and then purged with argon.
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (125 mg, 0,20 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (19 ml) was added.
  • the mixture was heated to 80 0 C with stirring until the BINAP dissolved.
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (30 mg, 0,135 mmol) was added.
  • the flask was recapped with the septum and then purged with argon.
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (70 mg, 0.11 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (9.7 ml) was added.
  • the mixture was heated to 80 0 C with stirring until the BINAP dissolved ( ⁇ 1 min).
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (16 mg, 0.07 mmol) was added.
  • the flask was recapped with the septum and then purged with argon (for -30 sec).
  • Reagents and conditions i) H 2 60 psi, 10% Pd/C ethyl acetate, rt 4h; ii) methyl 2-Br-benzoate Cs 2 CO 3 Pd(OAc) 2 ( ⁇ ) BINAP toluene, 8O 0 C 15.5 h; iii) BBr 3 CH 2 CI 2 -45°C 19.5 h then rt. 23 min. iv) 2-methoxy-1-bromo-naphtalene, Cs 2 CO 3 Pd(OAc) 2 ( ⁇ ) BINAP toluene, 80 0 C;
  • 2-Methoxy-1-naphthalenamine was obtained with the same procedure reported above, (step /,scheme1 ) using 2-methoxy-1-nitronaphthalene (3.00 g, 14.8 mmol) as starting material.
  • the 2-methoxy-1-naphthylenamine (2.6 g, 100 %) obtained was used for the next reaction without further purification.
  • the ( ⁇ ) BINAP (200 mg, 0,323 mmol), palladium acetate (50 mg, 0,218 mmol) and toluene (29 ml) were added. The mixture was heated to 8O 0 C with stirring for 15h.
  • the ( ⁇ ) BINAP (200 mg, 0,323 mmol), palladium acetate (50 mg, 0,218 mmol) and toluene (29 ml) were added. The mixture was heated to 8O 0 C with stirring for 24h .
  • Reagents and conditions i) DPEphos,Pd 2 dba 3 , toluene,t-Buok,100°C, argon ii) BBr 3 CH 2 Cl 2 -45 0 C 15 h then rt 6,45 h; iii) MeOH, oxone, O 0 C then rt 16 h; ST3500 iv) BBr 3 CH 2 Cl 2 -45°C 20 min. then rt 2Oh Step i - preparation of:
  • Step i preparation of: 4-fluoro-N-(4-fluorophenv ⁇ naphthalen-1 -amine ( ST35981
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (160 mg, 0,25 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (24 ml) was added.
  • the mixture was heated to 80 0 C with stirring until the BINAP dissolved.
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (40 mg, 0,17 mmol) was added.
  • the flask was recapped with the septum and then purged with argon.
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (140 mg, 0,22 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (21 ml) was added.
  • the mixture was heated to 80 0 C with stirring until the BINAP dissolved.
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (33 mg, 0,147 mmol) was added.
  • the flask was recapped with the septum and then purged with argon.
  • a dried flask was purged with argon and charged with ( ⁇ ) BINAP (160 mg, 0,25 mmol) and capped with a rubber septum.
  • the flask was purged with argon and toluene (24 ml) was added.
  • the mixture was heated to 80 °C with stirring until the BINAP dissolved.
  • the solution was cooled to room temperature, the septum was removed, and palladium acetate (40 mg, 0,17 mmol) was added.
  • the flask was recapped with the septum and then purged with argon.
  • Example 7 General analytical methods Melting points were determined on a Bibby Stuart Scientific SMP1 melting point apparatus and are uncorrected.
  • the anti-aggregating activity of the compound of formula (I) on the peptide ⁇ A-i -42 is carried out via the binding of the thioflavin T according to the following procedure.
  • the ⁇ -A ( i -42 ) was dissolved in a mixture of Acetonitrile and distilled water (CH 3 CN/H 2 O 1 :1 ) to the final concentration of 1 mg/mL The solution was divided in aliquots of 2 ml_ and stored at -8O 0 C until the use. The work solution was prepared diluting the stock solution five times with H 2 O (final concentration 44. ⁇ mol/L).
  • the ⁇ -A ( i -42 ) was dissolved in a mixture of Acetonitrile and distilled water (CH3CN/H2O 1 :1 ) to the final concentration of 1 mg/mL. An aliquot of 2 ml_ was freeze-dried to eliminate the trifluoroacetic acid residual of the peptide synthesis. The ⁇ -A(i -42 ) peptide was subsequently dissolved in 0.1 ml_ of DMSO and 5.0 ml_ of 2xPBS, pH 7.4.
  • the ⁇ -A (1-42 ) was incubated to 37°C for 8 days, at the end, after sonication, it was diluted five times with 2xPBS (final concentration 17.4 ⁇ mol/L). Waiting to be used, the aggregate ⁇ -A ( i -42) was divided in aliquots and stored at -8O 0 C. Fluorescence measurement with thioflavin T
  • the assay was performed in triplicate in 96-well plates as reported above in scheme. Test compounds were added in the wells containing the aggregate ⁇ -A ( i_ 42 ) then, 15 after minutes, the non-aggregate ⁇ -A ( i -42 ) was added. The 96-well plates were incubated at 37°C under agitation for 24 hours. The following day, a volume of 200 ⁇ l_ of a solution containing 10 ⁇ mol/L thioflavin T and 50 ⁇ mol/L Na 2 HPO 4 pH 6.5 was added to each well.
  • WALLAC VICTOR 2 fluorescence spectrophotometer
  • the % of aggregation was determinated by the following formula: ( ⁇ Amyloid+Test compound) - ( Blank+Test compound) x 100 (Control+ ⁇ Amyloid) - Blank Results
  • Table A shows the IC 50 of the compounds.
  • the results on compound ST1859 (1- [(2-hydroxy-1-naphthyl)methyl]-2-naphthol) (see WO02/00603) have been reported for comparative purposes.
  • mice and rats were used. Animals were divided into groups and received compound subcutaneously or intravenously and were killed by decapitation 0, 15, 30, 60, 120, 180 and 240 min after dosing to determine plasma and brain concentrations of compounds. Compounds were determined in plasma by high- performance liquid chromatography (HPLC) after a solid liquid extraction procedure. Briefly, Oasis HLB 1cc cartridges were pre-wetted with methanol and distilled water. Then internal standard, mouse plasma or rat plasma were added and the cartridges were washed with mater-methanoland methanol, interrupting the vacuum before the column was completely dry after each passage.
  • HPLC high- performance liquid chromatography
  • the compound was removed by eluiting the cartridges with methanol and evaporated to dryness under nitrogen. The residue was dissolved in the mobile phase centrifuged and analyzed by HPLC with UV detection (224 nm). Separation was done on a ⁇ Bondapack C18 column protected by a LiChrosphere RP-8 pre-column at room temperature.
  • the mobile phase was CH 3 CN:CH 3 OH:0.001M KH 2 PO 4 (40:10:50 v/v) delivered at a flow rate of 1.2 mL/min.
  • Brain tissue was homogenized (1g/10ml) in CH 3 CN:0.001M phosphate buffer, pH 7.4 and a volume containing approximately 100 mg of tissue was centrifuged. The supernatant was processed as for plasma.
  • AUCt Mean brain and plasma area under the concentration-time curve (AUCt) were determined using the linear trapezoidal rule and extrapolated to infinity (AUC) by the concentration method.
  • the elimination rate constant was calculated by least squares regression analysis of the terminal log-linear portion of the plasma and the brain drug concentration curves.
  • the maximum concentration (Cmax) and the time (t max ) of its occurrence were read directly from the plasma and brain concentration time data.
  • Table B show the plasma and brain concentration-time curves of compound ST2175 after s.c. injection (25 mg/kg) in mice.
  • Table C shows the plasma and brain AUC of compound ST2175 after s.c. injection (25 mg/kg) in mice.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compounds useful in the treatment of disorders characterised by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below. where the radicals have the meaning indicated in the description.

Description

NAPHTHYL DERIVATIVES INHIBITORS OF THE BETA-AMYLOID
AGGREGATION
FIELD OF THE INVENTION
The present invention relates to new compounds useful in the treatment of disorders characterised by deposits of amyloid aggregates, as well as to the pharmaceutical compounds containing the same together with pharmaceutically acceptable excipients. BACKGROUND OF THE INVENTION
The presence of amyloid deposits and changes in the neuronal cytoskeleton are among the clearest signs of Alzheimer's disease (AD). These two events, which involve mainly the cerebral cortex at an early stage, even if the final pathological picture of the disease involves the whole central nervous system, are a necessary, even if not a sufficient, condition for the onset of the disease (Chen M. (1998) Frontiers in Bioscience 3a, 32-37). In general, irrespective of the protein from which it is formed, the amyloid substance has the characteristics of consisting of fibres 7-8 nm in diameter, of having an affinity for the Congo Red stain and of not being soluble in water. In AD, the amyloid fibres accumulate outside the cell, in the intracellular spaces of the brain and in the tunica media of the cortical and meningeal arterioles, producing three different macroscopic changes: senile plaques and diffuse plaques, which can be differentiated between in that there is the presence or absence of a change in the neuronal processes around the central amyloid deposit, and amyloid angiopathy, which is the expression of the infiltration of amyloid fibres in the wall of the arteries, between the smooth muscle fibres and the internal elastic lamina. Apart from the formation of amyloid and helical filaments, a very serious synaptic rarefaction has been found in the cortex of subjects suffering from AD. Approximately 80%-90% of the neuronal contacts are destroyed in the final stage of the disease and this change is the real pathological correlate of dementia. Analysing the progress of dementia, it appears certain that amyloid is the early and primary change in the disease and that the intraneuronal helical filaments are the intermediate expression of the damage to the neurons which, ultimately, lose the synaptic contacts, with the subsequent clinical effect of the deterioration in mental functions.
The soluble form of a particular type of β-amyloid, βAi-42, hitherto considered to be toxic only in its aggregated form, is implicated in the progressive loss of memory and of the cognitive functions of Alzheimer's patients. βAi-42, produced in the initial stage of the disease, suppresses the activity of pyruvate dehydrogenase which promotes the synthesis of ACh providing for the transportation of acetyl-CoA, reducing the release of the neurotransmitter, changing the synaptic connections and causing the cholinergic deficits responsible for the disease (Hoshi M., Takashima A., Murayama M., Yasutake K., Yoshida N., lshiguro K., Hoshino T., lmahori K. (1997) The Journal of Biological Chemistry 272:4, 2038-2041).
It is known that a number of the stains bind to the amyloid fibres in a specific way and the most important of these is Congo Red (CR) (Lorenzo A. and Yankner B.A, 1994 PNAS 91 ;12243-12247).
This stain causes an increase in birefringence of the amyloid fibres and produces a characteristic circular dichroism indicative of a specific interaction between the stain and the substrate (the fibres) enabling diagnosis of amyloidosis in the tissue. The protein β-amyloid (βA) derives from the proteolytic action of a number of enzymes which act specifically on the precursor of the amyloid protein (βAPP) (Vassar R. et al. 1999 Science 286;735-740).
There are many mechanisms by which the β-amyloid fragment can induce neurotoxic effects. In the first place immunohistochemical studies have revealed the presence, in the senile plaques, of inflammation interleukins (IL-1 , IL-6), complement factors, other inflammatory factors and lysosomial hydrolases. It has been demonstrated that the β-amyloid protein is capable of stimulating the synthesis and secretion of IL-1 , IL-6 and IL-8 by the microglial cells and therefore of activating the cytotoxic mechanisms of acute inflammation (Sabbagh M. N.,
Galasko D., Thai J. L. (1997) Alzheimer's Disease Review 3, 1-19). The presence of activated microglia in postmortem Alzheimer disease specimens is used to support the argument that inflammation contributes to Alzheimer pathogenesis
(Morgan D. et al, (2005) J. Neuropathol Exp. Neurol 64(9):743-753) Diseases characterised by deposits of amyloid aggregates include, apart from Alzheimer's disease, Down's syndrome, hereditary cerebral haemorrhage associated with amyloidosis of the "Dutch type", amyloidosis accompanied by chronic inflammation, amyloidosis accompanied by multiple myeloma and other dyscrasias of the haematic "B" lymphoid cells, amyloidosis accompanied by type Il diabetes, amyloidosis accompanied by prion diseases such as Creutzfeldt-Jakob disease and Gerstmann-Straussler syndrome, kuru and ovine scrapie.
In general, however, the damage caused by βA may be summarised as follows:
1. changes in amyloidogenesis; 2. increase in the vulnerability of neurons to excitotoxicity;
3. increase in the vulnerability of the neurons to hypoglycaemic damage;
4. changes in the homeostasis of calcium;
5. increase in damage by oxidation; 6. activation of the inflammatory mechanisms;
7. activation of the microglia;
8. induction of lysosomial proteases;
9. changes in the phosphorylation of the protein tau;
10. induction of apoptosis; 11. damage to the membranes.
From a purely theoretical point of view, the reduction in the damage caused by βA can be dealt with by different therapeutic approaches: a) reducing the production of βA using inhibitors of the secretases to change the metabolism of the APP (increasing the α or reducing the β and γ secretases); b) preventing or blocking the aggregation of the βA; c) increasing the clearance of the βA; d) blocking the neurotoxic effects of βA restoring calcium homeostasis; e) preventing the toxicity produced by the free radicals; f) preventing excitotoxicity; g) reducing the damage caused by the inflammatory response; h) correcting the imbalance between zinc and copper; i) inhibiting neuronal apoptosis
(Sabbagh M. N., Galasko D., Thai L.J. (2000) Alzheimer's Disease Review 3-4, 231-59; Rogers J.Y. and Lahiri D. K. (2004) Curr Drug Targets 6:535-551 ; Jacobsen J.S. (2002) Curr. Top Med Chem (2002) 4:343-52; Dodel R.C. , Hampel H., Du Y. (2003) Lancet Neurol 4:215-20).
To date no specific therapy exists to prevent, slow down or arrest the amyloidogenic process at the root of Alzheimer's disease. Indeed the treatments currently used for this disease are exclusively symptomatic and, even if they act on various aspects, they fundamentally only interfere with the neurotransmitter mechanisms which govern learning and memory. The substances mostly used include the reversible inhibitors of acetylcholinesterase, such as tacrine, donepezil and rivastigmine. Furthermore, the only diagnostic tools currently available to diagnose
Alzheimer's disease are behavioural examinations and clinical "scores", while, due to an absence of suitable tracers, radiographic or scanning procedures are not yet able to accurately distinguish between degeneration of an Alzheimer's type and other degenerative phenomena. The problems encountered in treating Alzheimer's disease, the severity of this disease and the difficulty of diagnosing it, make it desirable to not only find new drugs which are able to cure or slow down the progress of the disease but also discover compounds to be used in radiographic and scanning procedures capable of diagnosing it. The Applicant had earlier discovered (WO02/00603) that pamoic acid, or one of its derivatives, or one of its analogues, or one of their pharmaceutically acceptable salts, are effective in the treatment and in the prevention of Alzheimer's disease and diseases characterised by deposits of amyloid aggregates. Published patent application US 2004/0229869 discloses and claims mercatophenyl naphthyl methane compounds, which are said to be potentially useful in the treatment of osteoporosis.
Published patent application US 2005/0119225 discloses and claims N- substituted aniline and diphenylamine analogs, which are said to be PDE4 inhibitors.
Published patent application US 2004/0053890 relates to naphthalene derivatives whose biological activity would be linked to the cannabinoid receptor, thus potentially useful in the treatment of pain and inflammation. These compounds are defined by a general formula, according to which the naphthyl group always brings two substituents in positions 1 and 4. Focussing on the synthesized compounds, those in which the substituent in position 1 is NH, S or SO2 (see Table at page 6) in position 4 always present the radical pentyl-oxy.
German patent DE 343057 claims the synthesis of 1-arylamino-4- oxynaphthalines.
Published patent application US 2004/0132769 relates to phenylacetic acid derivatives reported to have an activity as selective COX-2 inhibitors.
Moosmann et al. (see Biol. Chem., 382., 1601-12, 2001) report the protective activity of some aromatic amines and imines against oxidative nerve cell death. According to this study the compounds, which showed superior effects among those tested in the antioxidant neuroprotection, were iminostilbene, phenoxazine and phenothiazine and in general imines were shown to be more potent than the corresponding amines. The blood brain barrier crossing always represents one the main problems for all the compounds acting on the CNS. Therefore there is always the need of discovering compounds that, while maintaining or improving the efficacy in all the in-vitro tests, are also able to cross the blood brain barrier.
DESCRIPTION OF THE INVENTION
The Applicant has now surprisingly found new compounds which are effective in the treatment of the diseases referred to. These compounds tested on animals have also shown the capability to cross the blood brain barrier. These results are reported in the section entitled Examples.
The Applicant has also found that some compounds, whose structure and synthesis has already been reported, show unexpectedly interesting pharmacological activity in the same field.
One of the main objects of the present invention is the use of the compounds of Formula (I) as follows, for the preparation of pharmaceutical compounds useful in the treatment of conditions characterised by deposits of amyloid aggregates.
Figure imgf000008_0001
where: R is selected from the group consisting of H, OR3, COOR3, N(R3)2, NO2, halogen, hydroxyalkyl Ci-C3;
Ri and R2 are the same or different and are selected from the group consisting of
H; OR3; COOR3; linear or branched, saturated or unsaturated Ci-C4 alkyl; N(R3)2; CrC4 linear or branched, saturated or unsaturated alkylthio; halogen; and
SO2N(R3)2;
R3 is selected from the group consisting of H; Ci-C4 linear or branched alkyl;
PO3H2,- and PO3(CH3)2;
A is selected from the group consisting of NR4; S; and SO2; R4 is selected from the group consisting of H; Ci-C4 linear or branched alkyl; Ci-
C4 linear or branched alkanoyl; and
B is a phenyl or naphthyl group.
According to independently preferred embodiments of the invention A is NH, Ri is
H, R2 is selected from the group consisting of H, COOH, COOCH3 and OH; and R is selected from the group consisting of H, OH and OCH3.
The following Table 1 lists some of the compounds, together with their structural formula, whose use according to the invention is preferred.
Table 1
Figure imgf000009_0001
ST2763 methyl 4-(1-naphthylamino)benzoate
ST2764 4-(1-naphthylamino)benzoic acid
Figure imgf000010_0001
COOH
ST2177 4-(4-hydroxyanilino)-1 -naphthol
ST2176 4-anilino-1 -naphthol
Figure imgf000010_0002
ST2757 2-[(2-hydroxy-1 -naphthyl)amino]benzoic acid
ST2756 (1-methoxy-2-naphthyl)phenylamine
ST2173 4-methoxy-N-phenyl-1-naphthalenamine
ST3499 1 -methoxy-4-[(4-methoxyphenyl) sulfonyljnaphthalene
ST3500 4-[(4-hydroxyphenyl)sulfonyl]-1 -naphthol
Figure imgf000010_0003
Another object of the present invention are the compounds of general Formula (I)
Figure imgf000011_0001
(I) where:
R is selected from the group consisting of H, OR3, COOR3, N(R3)2, NO2, halogen, hydroxyalkyl CrC3;
Ri and R2 are the same or different and are selected from the group consisting of
H; OR3; COOR3; linear or branched, saturated or unsaturated Ci-C4 alkyl; N(R3)2; CrC4 linear or branched, saturated or unsaturated alkylthio; halogen; and
SO2N(R3)2; provided that Ri and R2 are not both H or halogen;
R3 is selected from the group consisting of H; C1-C4 linear or branched alkyl;
PO3H2; and PO3(CH3)2;
A is selected from the group consisting of NR4; S; and SO2; R4 is selected from the group consisting of H; Ci-C4 linear or branched alkyl; Ci-
C4 linear or branched alkanoyl; and
B is a phenyl or naphthyl group, with the proviso that: when A is NR4, Ri and R2 are not both OR3; and with the exception of the following compounds:
4-methoxy-N-phenyl-1-naphthalenamine (ST2173),
1-hydroxy-N-phenylnaphthalen-2-aminium chloride (ST2762), methyl 4-(1-naphthylamino)benzoate (ST2763),
4-(1-naphthylamino)benzoic acid (ST2764),
4-(4-hydroxyanilino)-1-naphthol (ST2177),
4-anilino-1-naphthol (ST2176), 2-[(2-hydroxy-1-naphthyl)amino]benzoic acid (ST2757),
(1 -methoxy-2-naphthyl)phenylamine (ST2756);
1 -methoxy-4-[(4-methoxyphenyl)sulfonyl]naphthalene (ST3499); and
4-[(4-hydroxyphenyl)sulfonyl]-1-naphthol (ST3500).
As a matter of fact the synthesis of all the compounds listed here above has been mentioned in previous publications, specifically as follows:
ST2756: Bowman, D. F.; Middleton, B. S.; Ingold, K. U. Oxidation of amines with peroxy radicals. I. N-phenyl-2-naphthylamine. Journal of Organic Chemistry
(1969), 34(11 ), 3456-61 ;
ST2763: Seki, Mieko; Yoneyama, Hiroto; Okuda, Daisuke; Hirose, Eiichi; Ozaki, Tadayoshi; Agata, Takashi; Ishii, Tom; Mashimo, Kiyokazu; Sato, Katsuhiro.
Electric charge-transportable polymers with high glass transition temperature, good solvent solubility, film-forming property and thermal stability. Jpn. Kokai
Tokkyo Koho (2003), 34 pp;
ST2764: Wagner, Eugene Ross; Allen, Bobbie Jewel; Renzi, Alfred Arthur, p- Aminobenzoic acids with hypolipemic action. Ger. Offen. (1977), 13 pp;
ST2757: Mehta, R. K.; Gupta, R. K.; Singhi, V. C. Uranium(VI) complexes of some tridentate Schiff bases. Israel Journal of Chemistry (1971), 9(5), 589-91 and Ozha, D. D.; Mehta, R. K. Stepwise formation and thermodynamic constants of europium, gadolinium, dysprosium and holmium complexes of some tridentate Schiff bases. Transactions of the SAEST (1979), 14(3), 141-4; ST2176: Hotta, Seiji; Ito, Yukiaki; Hatori, Minoru. Fluoran derivatives. Jpn. Kokai Tokkyo Koho (1975), 18 pp; and Yuan, Xin-hua; Xu, Hong-xing; Ni, Zhong-hai; Zhang, Li-fang; Wei-Xian-yong. Study on the reaction of aromatics containing active hydrogen atom with nitrobenzene catalyzed by aluminum trichloride. Ranliao Huaxue Xuebao (2004), 32(1), 104-108; ST2173: Justus Liebigs Ann. Chem. (1925) 443, 222; ST2762: Bull.soc.chim.(1925), 37, 890-901 ; ST3499: US4996279 -US4960912; and ST3500: US4996279-US4960912.
The present invention also comprises tautomers, geometrical isomers, optically active forms as enantiomers, diastereomers and racemate forms, as well as pharmaceutically acceptable salts of the compounds of Formula (I).
Preferred pharmaceutically acceptable salts of the Formula (I) are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, andpara-toluenesulfonate salts.
According to independently preferred embodiments of the invention: A is NH, R is selected between OH and OCH3 and/or is present on the naphthyl group in ortho position with respect to A, Ri is selected among OCH3, COOCH3, H, COOH and R2 is selected among H, I, OH and OCH3. Within the framework of the present invention, examples of linear or branched C1-C4 alkyl group, are understood to include methyl, ethyl, propyl, butyl, and their possible isomers, such as, for example, isopropyl, isobutyl and ter-butyl.
The following Table 2 lists some of the most preferred compounds according to the invention together with their structural formula.
Table 2
ID No. Name Structure
ST2759 methyl 2-[(2-hydroxy-1 -naphthyl)amino]benzoate
ST2760 methyl 2-[(2-methoxy-1 -naphthyl)amino]benzoate
ST1972 4-[(4-methoxy-1 -naphthyl)amino]benzoic acid
ST1973 4-[(4-hydroxy-1 -naphthyl)amino]benzoic acid
ST2878 N-(5-iodo-2-methoxyphenyI)-N-(4-methoxy-1- naphthyl)amine
ST2879 N-(4-methoxy-1 -naphthyl)-N-(2- methoxyphenyl)amine
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Another object of the present invention is the use of the compounds of Formula (I) as medicines, or, in other words, as active principles of drugs, in particular for the treatment of diseases characterised by deposits of amyloid aggregates.
A further object of the present invention is the use of the compounds of Formula (I) referred to above or one of their pharmaceutically acceptable salts, for the preparation of pharmaceutical compositions useful in the treatment of disorders characterised by deposits of amyloid aggregates. The compounds of Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used, unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures.
A further object of the present invention is a process for preparing general formula compounds (I). According to preferred embodiments of the invention some of such processes are reported in the section entitled Examples and are diagrammatically represented by some Schemes (see in particular Schemes 1 to
6).
Generally speaking the compounds of Formula (I) may be obtained starting from a substituted or un-substituted nitro naphthalene. The nitro naphthalene is hydrogenated with catalyst such as Pd/C in organic solvent such as ethyl acetate.
The amine so obtained is condensed with a substituted or un-substituted aryl halide derivative, with the reagent BINAP [2,2'-Bis(diphenylphosphino)-1 ,1'- binaphthyl] and Palladium acetate. Next steps are deprotection of ether with BBr3 and or hydrolysis of ester with NaOH.
A method of treating a mammal suffering from a pathology characterized by deposits of amyloid aggregates, comprising administering a therapeutically effective amount of a compound of Formula (I) as described above represents one of the aspects of the present invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate a targeted disease or condition, or to exhibit a detectable therapeutic effect.
For any compound, the therapeutically effective dose can be estimated initially in in vitro assays, for example by measuring the residual aggregated beta- amyloid after incubation with the compounds of the invention; or in animal models, usually mice, rats, rabbits, dogs, pigs or monkeys, such as for example the amyloid precursor protein (APP)-transgenic mice.
The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination (s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 100 mg/kg, preferably 0.05 mg/kg to 50 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones. The medicament may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co. , N. J.1991).
Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient. Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.
The medicament of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, rectal means or locally on the diseased tissue after surgical operation.
Dosage treatment may be a single dose schedule or a multiple dose schedule. A further object of the present invention are pharmaceutical compositions containing one or more of the compounds of formula (I) described earlier, in combination with excipients and/or pharmacologically acceptable diluents.
The compositions in question may, together with the compounds of formula (I), contain other known active principles.
A further embodiment of the invention is a process for the preparation of pharmaceutical compositions characterised by mixing one or more compounds of formula (I) with suitable excipients, stabilizers and/or pharmaceutically acceptable diluents. A further object of the present invention is the use of the compounds of
Formula (I) referred to above, for the preparation of a diagnostic kit for diagnosing conditions characterised by deposits of amyloid aggregates.
Indeed, the compounds according to the present invention may contain in their molecular structure atoms of elements commonly used in diagnostic imaging. For example, radioactive isotopes of carbon, hydrogen, nitrogen, oxygen, iodine and indium can be introduced into their structure. And, more specifically, the compound of formula (I) can have at least one of the elements carbon, hydrogen, nitrogen or oxygen of its own molecular structure replaced by a corresponding radioactive isotope; or carry at least one atom of radioactive iodine; or it is in the form of a complex with radioactive indium.
These compounds containing radioactive isotopes may be prepared by analogy to those previously prepared as reported in the literature. Zhuang et al. (see Nucl Med Biol. 2005 Feb;32(2):171-84) report the preparation of biphenyls labeled with technetium" for imaging beta-amyloid plaques in the brain. Based on previously obtained Amyloid-beta plaque-specific biphenyls containing a p-N,N-dimethylaminophenyl group, a series of 99Tc and Re- N2S2-biphenyl derivatives was prepared.
Huang Y et al. (see J Med Chem. 2005 Apr 7;48(7):2559-70) have worked on fluorinated diaryl sulfides as serotonin transporter ligands. They have reported the synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. A serotonin transporter (SERT) ligand, [11C]2-[2-
(dimethylaminomethylphenylthio)]-5-fluorophenylamine was synthesized and evaluated as a candidate PET radioligand in pharmacological and pharmacokinetic studies. As a PET radioligand, AFA can be labeled with either C-
11 or F-18 (Huang Y et al., Nucl Med Biol. 2004 Aug;31 (6):727-38). All these radioactive compounds are useful for techniques such as PET
(Positron Emission Tomography), SPECT (Single Photon Emission Computerized Tomography) and planar scintigraphy. Alternatively, the compounds according to the present invention containing radioactive isotopes or atoms of elements useful as radio-opaque elements (for example iodine), can be used as complexing agents for elements commonly used in diagnostic imaging techniques, such as gadolinium for example (NMR), technetium (scanning techniques).
On the basis of this diagnostic application, the compounds according to the present invention are also useful for the prevention of the diseases indicated above. The invention will now be illustrated in greater detail by means of non- limiting Examples
EXAMPLES
Example 1 - Preparation of compounds of Formula (I) according to synthetic
Scheme 1
R3 = OCH3 1NO2
If R3 = OCH3
ST3245
Figure imgf000024_0001
ST2174
Figure imgf000024_0002
R1 = H, R2=H ST2176
R1 = 3-COOH, R2= 4-OH ST3717 R1 = 4OH, R2=H ST2177 ST3717 .HC1 = ST2511 R1 = 4COOCH3, R2=H ST2178
Reagents and conditions: i) H2 60 psi, 10% Pd/C ethyl acetate, rt 4h; ii) aryl halide Cs2CO3 Pd(OAc)2 (±) BINAP toluene, 800C 19-39 h; iii) BBr3 CH2Cl2 -45°C 1-15 h then rt 4.5-15 h;CH3COCl,MeOH iv) BBr3 CH2Cl2 -450C 15 h; v) IN NaOH, THF/ethanol 1 :1, reflux 3.5 h; Step i - Preparation of 4-methoxy-1-naphthalenamine
A suspension of 4-methoxy-1-nitronaphthalene (1.0 g, 4.9 mmol) in ethyl acetate (150 ml) was hydrogenated in Parr apparatus at room temperature in the presence of 10% Pd/C as a catalyst (200 mg) at an initial pressure of 60 psi for 4 h. The catalyst was removed by filtration and the filtrate was dried and evaporated to afford pure 4-metossi-1-naphthalenamine (850 mg, 100% yield), which was used for the next reaction without further purification. Step ii - Preparation of 4-methylbenzoate-1-yl(4-methoxy-1-naphthyl)amine (ST3244) A dried flask was purged with argon and charged with (±) BINAP (70 mg,
0.11 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (9.7 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved (~1 min). The solution was cooled to room temperature, the septum was removed, and palladium acetate (16 mg, 0.07 mmol) was added. The flask was recapped with the septum and then purged with argon (for -30 sec). The mixture was stirred at room temperature for 1 min, the 4-methoxy-1- naphthalenylamine (600 mg, 3.5 mmol) dissolved in toluene (1.5 ml) and methyl-4- bromobenzoate (615 mg, 2,9 mmol) were added, the septum was removed, and cesium carbonate (1.31 g, 4.0 mmol) was added. Additional toluene (7 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 800C with stirring for 24 h. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (980 mg) was then purified by column chromatography (ethyl acetate/n-hexane 1 :1 as eluent) to obtain 820 mg (77%) of pure ST3244. Mp 168- 170 0C (benzene); IR: v 3300 (NH), cm"1 ; 1H-NMR (CDCI3): δ 3.89 (s, 3H, COOCH3), 4.08 (S, 3H, OCH3), 6.03 (s broad, 1 H, NH), 6.45-6.71 (m, 2H, benzene C3-H and C5-H), 6.85 (d, J = 8.1 Hz, naphthalene H)1 7.39 (d, J = 8.1 Hz, naphthalene H), 7.48-7.61 (m, 2H, naphthalene H), 7.85-7.96 (m, 3H, naphthalene H and benzene C2-H and C6-H), 8.35-8.41 (m, 1 H1 naphthalene H).
The following compounds were obtained with the same procedure reported above. The reaction time, eluent for chromatographic system, yield, mp (recrystallization solvent), IR, and NMR data are reported for each derivative. 4-methoxy-N-phenyl-1 -naphthalenamine (ST2173): 21 h; ethyl acetate/n-hexane 1 :1 ; 70%; mp 141-143 0C (cyclohexane/n-hexane); IR: v 3400 (NH), cm"1; 1H- NMR (CDCI3): δ 4.07 (s, 3H, CH3), 5.75 (s broad, 1 H, NH), 6.75-6.90 (m, 4H, naphthalene H and benzene C2-H and C6-H), 7.15-7.25 (m, 3H, benzene C3-H, C4-H and C5-H), 7.50-7.60 (m, 2H, naphthalene H), 8.04 (m, 1 H, naphthalene H), 8.33 (m, 1 H, naphthalene H). 4-methoxy-N-(4-methoxyphenvO-1 -naphthalenamine (ST2175): 21 h; ethyl acetate/n-hexane 1 :1 ; 96%; oil; IR: v 3380 (NH), cm"1 ; 1H-NMR (CDCI3): δ 3.81 and 4.04 (2s, 6H, CH3), 5.90 (s broad, 1 H, NH), 6.74-6.85 (m, 6H, naphthalene C2-H and C3-H and benzene H), 7.51-7.58 (m, 2H, naphthalene H), 8.04 (m, 1 H, naphthalene H), 8.35 (m, 1H, naphthalene H). N-(4-methoxy-1 -naphthvπ-N-(2-methoxyphenvπamine (ST2879): 39 h; ethyl acetate/n-hexane 1 :2; 70%; mp 108-110 0C (cyclohexane); IR: v 3395 cmJ (NH); 1H-NMR (CDCI3): δ 3.98 and 4.02 (2s, 6H, CH3), 6.60 and 6.91 (2m, 2H, benzene C3-H and C6-H), 6.73 (m, 2H, benzene C4-H and C5-H), 6.80 (d, 1 H, J0 = 8.1 Hz, naphthalene C3-H), 7.35 (d, 1 H, J0 = 8.1 Hz, naphthalene C2-H), 7.48 (m, 2H, naphthalene C6-H and C7-H), 7.98 and 8.30 (2m, 2H, naphthalene C5-H and C8- H).
The following derivatives were obtained using a procedure similar to that reported above. Some reagents were used in a different ratio as explained below. Λ/-(5-iodo-2-methoxyphenyl)-4-methoxy-1-naphthalenamine (ST2878): the reaction was performed on 1.04 g (6.0 mmol) of 1-methoxy-4-naphthalenamine. 19 h, then BINAP (60 mg, 0.095 mmol), palladium acetate (20 mg, 0.06 mmol), toluene (9 ml); 9 h, then BINAP (120 mg, 0.19 mmol), palladium acetate (30 mg, 0.13 mmol), toluene (18 ml); 24 h, then BINAP (120 mg, 0.19 mmol), palladium acetate (30 mg, 0.13 mmol), toluene (18 ml), 2,4-diiodoanisole (1.8 g, 5.0 mmol); 48 h; flash chromatography, ethyl acetate/n-hexane 1 :20; 18%; oil; IR: y 3390 cm"1 (NH); 1H- NMR (CDCI3): δ 3.95 and 4.03 (2s, 6H, CH3), 6.61 (d, 1H, J0 = 8.3 Hz, benzene C3-H), 6.78 (d, 1 H, Jm = 2.0 Hz, benzene C6-H), 6.82 (d, 1 H, J0 = 8.1 Hz, naphthalene C3-H), 7.01 (dd, 1 H, J0 = 8.3 Hz, Jn, = 2.0 Hz, benzene C4-H), 7.34 (d, 1H, J0 = 8.1 Hz, naphthalene C2-H), 7.50 (m, 2H, naphthalene C6-H and C7- H), 7.92 and 8.31 (2m, 2H, naphthalene C5-H and C8-H). 4-methoxy-3-methylbenzoate-1 -yl(4-methoxy-1 -naphthvDamine (ST3245): Performed on 4-methoxy-1-naphthalenamine (1.6 g, 9.1 mmol), using (±) BINAP (470 mg, 0.76 mmol), palladium acetate (120 mg, 0.51 mmol) at 1200C. 24 h; ethyl acetate/n-hexane 1 :1 ; 97%; oil; IR: v 3320 (NH), 1695 (CO) cm"1 ; 1H-NMR (CDCI3): δ 3.88 (s, 3H, OCH3), 3.89 (s, 3H1 OCH3), 4.04 (s, 3H, OCH3), 5.60 (s broad, 1 H, NH), 6.79 (d, 1 H, J = 8.2 Hz, naphthalene H), 6.88 (m, 2H, benzene C3-H and C4-H), 7.22 (d, 1 H, J = 8.2 Hz, naphthalene H), 7.34 (m, 1 H, benzene C6-H), 7.50-7.58 (m, 2H, naphthalene H), 7.99 and 8.34 (2m, 2H, naphthalene). N-(4-methoχyphenvπ-4-nitronaphthalen-1 -amine (ST3451)
A dried flask was purged with argon and charged with (±) BINAP (50 mg, 0,08 mmol) and capped with a rubber septum. The flask was purged with argon and dioxane (7,5 ml) was added. The mixture was heated to 100 0C with stirring until the BINAP dissolved. The solution was cooled to room temperature, the septum was removed, and palladium acetate (13 mg, 0,055 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, the 1-amino-4-nitro-naphthalene (500 mg, 2,7 mmol) and a solution of 4-bromo-anisole (410 mg, 2,2 mmol ) dissolved in dioxane (2 ml) were added, the septum was removed, and cesium carbonate (1 ,00 g, 3,08 mmol) was added. Additional dioxane (6 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 1000C under stirring for 21 h and 15 min. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.055 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 1000C for 4h and 30min. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.55 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 100°C for 3 days. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.055 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 1000C for 24h. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.055 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 100°C for 2Oh. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.055 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 100°C for 24h. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.055 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 1000C for 16h. A solution of (±) BINAP (50 mg, 0,08 mmol) and palladium acetate (13 mg, 0.055 mmol) dissolved in dioxane (7.5 ml) was added and stirred at 1000C for 4h and 30min.The mixture was cooled to room temperature, diluted with methanol, filtered, and concentrated in vacuo. The crude product (2.86 g) was purified by column chromatography (Chloroform as eluent) to obtain 220 mg (38%) of pure ST3451; IR: v 3365 (NH), cm"1; 1H-NMR (DMSO-c/6): δ 3,93(s, 3H, CH3), 6.77 (s broad, 1 H, NH), 6.85 (m, 1 H, naphthalene H), 7.05 (d, 2H, J0= 8.8 Hz, benzene C3-H and C5-H), 7.30 (d, 2H, J0= 8.8 Hz, benzene C2-H and C6-H), 7.67 and 7.81 (2m, 2H, naphthalene C6-H and C7-H), 8.08, 8.39 and 9.07 (3m, 3H, C2-H, C5-H and C8-H naphthalene).
Step Hi- Preparation of 2-r(2-hvdroxy-1-naphthyl)amino1benzoic acid (ST1973).
A solution of methyl 4-(4-methoxy-1-naphthalenylamino)benzoate (ST3244) (763 mg, 2.4 mmol) in dichloromethane (27 ml) was added dropwise to 1M BBr3 (12.6 ml, 12.6 mmol) in the same solvent at -45°C, under argon atmosphere. The mixture was stirred for 15 h at the same temperature, and then treated with water (50 ml). The mixture was extracted with ethyl ether (3 x 50 ml) and the organic extracts were collected, washed with brine (3 x 100 ml) and dried. Evaporation of the solvent gave a crude product which was chromatographed (ethyl acetate/n- hexane 9:2 as eluent) to afford pure ST1973,301mg,45%; mp 214-217 0C (toluene); IR: v 3360 (OH, NH), 2800 (COOH) cm"1 ; 1H-NMR (DMSO-d6): δ 6.63 (d, 2H1 J0 = 8.7 Hz, benzene C3-H and C5-H), 6.92 (d, 1 H, J = 8.0 Hz, naphthalene H), 7.27 (d, 1 H, J = 8.0 Hz, naphthalene H)1 7.50 (m, 2H, naphthalene H), 7.69 (d, 2H, J0 = 8.7 Hz, benzene C2-H e C6-H), 7.85 (m, 1 H, naphthalene H), 8.20 (m, 1H, naphthalene H), 8.45 (s broad, 1 H, NH), 10.20 (s broad, 1 H, OH), 12.15 (s broad, 1 H, COOH). 2-hvdroxy-5-F(4-hvdroxy-1-naphthyl) aminol benzoic acid ( ST3717)
A solution of 2-methoxy-5-(4-methoxy-1-naphthalenylamino)benzoic acid methyl ester ST3245 (500 mg, 1.5 mmol) in dichloromethane (18 ml) was added dropwise to 1M BBr3 (7.8 ml, 7.8 mmol) in the same solvent at -450C, under argon atmosphere. The mixture was stirred for 1 h at the same temperature, then warmed at room temperature and stirred for 15 h. After treatment with water (50 ml), the mixture was extracted with ethyl ether (3 x 50 ml) and the organic extracts were collected, washed with brine (3 x 100 ml) and dried. Evaporation of the solvent gave a crude product (300 mg), which was chromatographed (ethyl acetate as eluent) to afford pure ST3717 (75 mg, 17%); mp 175 0C dec; IR: v 3350 (OH, NH), 3000 (COOH) 1635 (CO) cm"1; 1H-NMR (DMSO-d6): δ 6.73 (d, 1 H, J0 = 8.7 Hz, benzene C3-H), 6.82 (d, 1 H, J = 8.0 Hz, naphthalene H), 6.97 (dd, 1 H, J0 = 8.7 Hz, Jm = 2.7 Hz, benzene C4-H), 7.05 (d, 1 H, J = 8.0 Hz, naphthalene H), 7.20 (d, 1 H, Jm = 2.7 Hz, benzene C6-H), 7.44-7.49 (m, 2H, naphthalene C6-H and C7- H), 7.99 (m, 1 H, naphthalene H), 8.15 (m, 1 H, naphthalene H), 9.85 (s broad, 3H, OH, COOH and NH). 2-hvdroxy-5-r(4-hvdroxy-1 -naphthvPaminolbenzoic acid hydrochloride (ST2511). Acetyl chloride (50 mg, 0.6 mmol) was carefully added in methanol (1 ml) cooled at 0 0C, under argon stream. Then, a solution of ST3717 (420 mg, 1.8 mmol) in methanol (13 ml) was added dropwise while the hydrochloric solution was gently stirred. After 15 min the solution was concentrated, isopropylic ether (50 ml) was added and the suspension was stirred at 00C for 10 min. The precipitate that formed was filtered, washed with cool methanol (1 ml) and then with isopropylic ether (3 x 2 ml) to give ST2511 (80 mg, 40 %). mp 220 0C dec. Step /V- Preparation of 4-anilino-1-naphthol (ST2176).
A solution of 4-methoxy-Λ/-phenyl-1-naphthalenamine (ST2173) (600 mg, 2.4 mmol) in dichloromethane (27 ml) was added dropwise to 1M BBr3 (12.6 ml, 12.6 mmol) in the same solvent at -45°C, under argon atmosphere. The mixture was stirred for 15 h at the same temperature, and then treated with water (50 ml). The mixture was extracted with ethyl ether (3 x 50 ml) and the organic extracts were collected, washed with brine (3 x 100 ml) and dried. Evaporation of the solvent gave a crude product (630 mg), which was chromatographed (ethyl acetate/n-hexane 1 :3 as eluent) to afford pure ST2176 (490 mg, 88%). Oil; IR: v 3375 (OH, NH) cm"1 ; 1 H-NMR (CDCI3): δ 5.30 and 5.65 (2s broad, 2H, OH and NH), 6.75-6.87 (m, 4H, naphthalene H and benzene C2-H and C6-H), 7.15-7.30 (m, 3H, benzene C3-H, C4-H and C5-H), 7.50-7.57 (m, 2H, naphthalene H), 8.05 (m, 1 H, naphthalene H), 8.25 (m, 1 H, naphthalene H).
The following derivatives were obtained with the same procedure reported above. 4-(4-hvdroxyanilino)-1 -naphthol (ST2177)
The solvents used for the preparation of ST2177 were purged with argon. The compound partially decomposed during chromatography. 15 h; ethyl acetate/n-hexane 1 :1 ; 100%; mp 74 0C dec; IR: v 3350 (OH, NH) cm"1 ; 1H-NMR (DMSO-de): δ 6.55-7.00 (m, 7H, naphthalene H, benzene H and NH), 7.38-7.47 (m, 2H, naphthalene H), 7.95-8.13 (m, 2H, naphthalene H), 8.67 and 9.67 (2s broad, 2H1 OH). methyl 4-r(4-hvdroxy-1-naphthv0amino1benzoate (ST2178): 15 h; ethyl acetate/π- hexane 1 :2; 58%; mp 188-190 0C (benzene/n-hexane); IR: v 3370 (NH, OH), 1680 (CO) cm-1 ; 1H-NMR (DMSO-d6): δ 3.73 (s, 3H, CH3), 6.60-6.67 (m, 2H, benzene C3-H and C5-H), 6.89 (d, 1 H, J = 8.0 Hz, naphthalene H), 7.24 (d, J = 8.0 Hz, naphthalene H), 7.44-7.48 (m, 2H, naphthalene H), 7.66-7.71 (m, 2H, naphthalene H), 7.68 (m, 2H1 benzene C2-H and C6-H), 7.82 (m, 1 H, naphthalene H), 8.17 (m, 1H, naphthalene H), 8.50 (s broad, 1H, NH), 10.18 (s broad, 1 H, OH). Step v- Preparation of 4-r(4-methoxy-1-naphthvDaminolbenzoic acid (ST1972)
A solution of ST3244 (500 mg, 1.5 mmol) and 1N NaOH (3.7 ml) in THF/ethanol 1 :1 (20 ml) was refluxed for 3.5 h while stirring. Then the mixture was poured onto crushed ice and extracted with ethyl acetate (30 ml). The aqueous layer was treated with 1 N HCI until pH 3 and then extracted with ethyl acetate (3 x 50 ml). The organic extracts were collected, washed with brine (3 x 100 ml), dried and the solvent was removed to yield ST1972 (240 mg, 50%). Mp 153-154 0C (isopropanol); IR: v 3400 (NH), 3000 (OH), 1650 (CO) cm-1 ; 1 H-NMR (DMSO-c/6): δ 4.01 (s, 3H, CH3), 6.70 (d, 2H, J0 = 8.5 Hz, benzene C3-H and C5-H), 7.01 (d, 1 H, J = 8.0 Hz, naphthalene C3-H), 7.39 (d, 1H, J = 8.0 Hz, naphthalene C2-H), 7.55 (m, 2H, naphthalene C6-H and C7-H), 7.71 (d, 2H, J0 = 8.5 Hz, benzene C2- H and C6-H), 7.90 (m, 1 H, naphthalene H), 8.20 (m, 1 H1 naphthalene H), 8.54 (s broad, 1 H1 NH).
The following derivative were obtained with a similar procedure. 2-methoxy-5-r(4-methoxy-1-naphthyl)amino1benzoic acid (ST2174V 3.5 h; 50%; mp 153-154 0C (isopropanol); IR: v 3300 (NH), 3160 (OH), 1690 (CO) cm-1; 1 H- NMR (DMSO-dβ): δ 3.76 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 6.91-6.98 (m, 3H, naphthalene H and benzene C3-H and C4-H), 7.16 (m, 1 H, benzene C2-H), 7.21 (d, 1 H, J = 8.2 Hz, naphthalene H), 7.53 (m, 2H, naphthalene H), 7.76 (s broad, 1H1 NH), 8.05 and 8.20 (2m, 2H, naphthalene H), 12.50 (s broad, 1H, OH). Example 2 - Preparation of compounds of Formula (I) according to synthetic Scheme 2
Scheme 2
Figure imgf000034_0001
Figure imgf000034_0002
ST2762 - HC1 OMe ST3456 OH ST3459
Figure imgf000034_0003
ST3453
Reagents and conditions: i) H2 60 psi, 10% Pd/C ethyl acetate, rt 4h; ii) Aryl halide , Cs2CO3 Pd(OAc)2 (±) BINAP toluene, 800C; iii) BBr3 CH2CI2 -45°C 0.5h.; acetylchloride,methanol, 0°C,15 min (ST2762)
IV) NaOH, EtOH/THF reflux
Step / - Preparation of 1-methoxy-2-naphthalenamine. 1-Methoxy-2-naphthalenamine was obtained with the same procedure reported for 4-methoxy-1-naphthalenamine using 1-methoxy-2-nitronaphthalene (3.70 g, 18.0 mmol) as starting material. The 1-methoxy-2-naphthylenamine (3.12 g, 100 %) obtained was used for the next reaction without further purification. Step H- Preparation of (1-methoxy-2-naphthyl)phenylamine (ST2756).
A dried flask was purged with argon and charged with (±) BINAP (70 mg, 0.11 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (9.7 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved (~1 min). The solution was cooled to room temperature, the septum was removed, and palladium acetate (16 mg, 0.07 mmol) was added. The flask was recapped with the septum and then purged with argon (for ~30 sec). The mixture was stirred at room temperature for 1 min, the 1-methoxy-2- naphthalenylamine (600 mg, 3.5 mmol) dissolved in toluene (1.5 ml) and bromobenzene (455 mg, 2,9 mmol) were added, the septum was removed, and cesium carbonate (1.31 g, 4.0 mmol) was added. Additional toluene (7 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 8O0C with stirring for 16 h. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product was then purified by column chromatography (ethyl acetate/ n- hexane 1 :1 as eluent) to obtain 854 mg (83%) of pure ST2756 mp 43-45 0C (n- hexane); IR: v 3395 (NH), cm"1 ; 1H-NMR (DMSO-Cf6): δ 3.80 (s, 3H, CH3), 6.85 (m, 1 H, benzene H), 7.07-7.65 (m, 8H, naphthalene H and benzene H), 7.84 (m, 1 H, naphthalene H), 7.93 (m, 1 H, naphthalene H), 7.99 (m, 1 H, naphthalene H). Methyl-4-r(1-methoxy-2-naphthvπ aminol benzoate (ST34521
A dried flask was purged with argon and charged with (±) BINAP (210 mg, 0,34 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (31 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved. The solution was cooled to room temperature, the septum was removed, and palladium acetate (50 mg, 0,23 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, the 1-methoxy-2-naphthalenamine (1 ,93 g, 11 ,16 mmol) (see Scheme 2 Step /), dissolved in toluene (6 ml) and methyl A- bromobenzoate (2,00 g, 13,02 mmol), the septum was removed, and cesium carbonate (4,24 g, 13,02 mmol) was added. Additional toluene (23 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 800C under stirring for 4h and 10 min. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (4,06 g) was then purified by column chromatography (Chloroform/ethyl acetate 9:1 as eluent) to obtain 2,78 g (97%) of pure ST3452. p.f. 153-154 0C (ligroina); IR: v 3327 (NH), 1691 (CO) cmJ; 1H-NMR (CDCI3): δ 3,95 (s, 3H, CH3), 7,14 (d, 2H, J0 = 8,8 Hz, benzene C2-H and C6-H), 7,44-7,48 (m, 1 H, naphthalene H), 7,55-7,59 (m, 1 H, naphthalene H), 7,64-7,69 (m, 2H, naphthalene H), 8,03 (d, 2H, J0 = 8,8 Hz, benzene C3-H and C5-H), 8,10 (m, 1 H, naphthalene H).
N-(4-iodophenvπ-1-methoxynaphthalen-2-amine(ST3454).
A dried flask was purged with argon and charged with (±) BINAP (125 mg, 0,20 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (19 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved. The solution was cooled to room temperature, the septum was removed, and palladium acetate (30 mg, 0,135 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, 1-methoxy-2-naphthalenamine (1 ,12 g, 6,5 mmol) (see Scheme 2 Step /), dissolved in toluene (4 ml) and 1 ,4-diiodobenzene (1 ,78 g, 5,4 mmol), the septum was removed, and cesium carbonate (2,46 g, 7,56 mmol) was added. Additional toluene (15 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 8O0C under stirring for 19h. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (3,72 g) was purified by column chromatography (Chloroform/petroleum ether 1 :1 as eluent) to obtain 740 mg (37%) of pure ST3454; p.f. 83-84 0C (n-hexane); IR: v 3327 (NH) cm"1; 1H-NMR (CDCI3): δ 3,96 (s, 3H, CH3), 6,97 (d, 2H, J0 = 8,8 Hz, benzene C2-H and C6-H), 7,40-7,43 (m, 1 H, naphthalene H), 7,55 (d, 2H, J0 = 8,8 Hz, benzene C3-H and C5-H), 7,57 (m, 1 H, naphthalene H), 7,85 and 7,07 (2m, 2H, naphthalene H). Step Hi - Preparation of 1-hvdroxy-N-phenylnaphthalen-2-aminium chloride (ST2762)
A solution of 1-Methoxy-Λ/-phenyl-2-naphthalenamine (ST2756) (705 mg, 2.4 mmol) in dichloromethane (27 ml) was added dropwise to 1M BBr3 (12.6 ml, 12.6 mmol) in the same solvent at -45°C, under argon atmosphere. The mixture was stirred for 30 minutes at the same temperature, and then treated with water (50 ml). The mixture was extracted with ethyl ether (3 x 50 ml) and the organic extracts were collected, washed with brine (3 x 100 ml) and dried. Evaporation of the solvent gave a crude product (630 mg), which was chromatographed (ethyl acetate/n-hexane 1 :3 as eluent) to afford pure 571 mg, 88%.; acetyl chloride (150 mg, 1.9 mmol) was carefully added in methanol (3 ml) cooled at 0 0C, under argon stream. Then, a solution of product pure(420 mg, 1.8 mmol) in methanol (3 ml) was added dropwise while the hydrochloride solution was gently stirred. After 15 min the solution was concentrated, isopropylic ether (17 ml) was added and the suspension was stirred at 00C for 10 min. The precipitate that formed was filtered, washed with cool methanol (1 ml) and then with isopropylic ether (3 x 2 ml) to give (170 mg, 33.5 %) di ST2762. Mp > 3000C; IR: v 3150 (NH e OH) cm"1 ; 1H-NMR (DMSO-Cf6): δ 6.70 (m, 1H, benzene H), 6.81-6.88 (m, 2H, benzene H), 7,07-7.16 (m, 2H, naphthalene H), 7.31-7.42 (m, 4H, benzene H and naphthalene H), 7.77 (m, 1 H, naphthalene H), 8.11 (m, 1 H, naphthalene H).
Methyl 4-r(1-hvdroxy-2-naphthvn amino! benzoate ( ST3456) 4-r(1-hvdroxy-2-naphthyl)amino1benzoic acid ( ST3459)
A solution of ST3452 (1 ,46 g, 4,75 mmol) in dichloromethane (54 ml) was added dropwise to 1M BBr3 Dichlorometane solution (23,7 ml, 23,7 mmol)at -45°C, under argon atmosphere. The mixture was stirred for 19 h and 40 min at the same temperature and also 35 min at room temperature. The mixture was diluted with water (100 ml) and extracted with ethyl acetate (3 x 100 ml); the organic layers were collected, washed with brine (3 x 100 ml), dried and concentrated under vacuo obtaining a crude product (1.02 g), which was purified by column chromatography (ethyl acetate/n-hexane 1 :1 as eluent) to afford ST3456 (610 mg) with same impurities and pure ST3459 (460 mg). ST3459: p.f. 210 (dec) 0C (MeOH); IR: v 3426 (OH, COOH), 3353 (NH), 1654 (CO) cm"1 ; 1 H-NMR (DMSO- d6): δ 6,78-6,80 (m, 2H, benzene C2-H e C6-H), 7,33-7,36 (m, 1H, naphthalene H), 7,42-7,50 (m, 3H, naphthalene H), 7,74-7,77 (m, 2H, benzene C3-H and C5- H), 7,84 7,86 (m, 1 H, naphthalene H), 8,18 (s broad, 1 H, NH), 8,19-8,21 (m, 1H, naphthalene H), 9,40 (s broad, 1 H, OH), 12,20 (s broad, 1H, COOH).
Unclear ST3456 was purified by column chromatography (acetone/n- hexane 1 :4 as eluent) obtaining pure ST3456 (500 mg). p.f. 175-176 0C (toluene); IR: v 3334 (OH and NH), 1684 (CO) cm-1 ; 1 H-NMR (DMSO-d6): δ 3.79 (s, 3H, CH3), 6,79 (d, 2H, benzene H), 6,64 (m, 1 H, benzene H), 7,17 (m, 1H, naphthalene H)1 7,28-7,31 (m, 2H, naphthalene H), 7,39 (m, 1 H, J0 = 8,8 Hz, benzene C2-H and C6-H), 7,35 (m, 1 H, naphthalene H), 7,45-7,51 (m, 3H, naphthalene H), 7,77 (m, 1H, J0 = 8,8 Hz, benzene C3-H and C5-H), 7,85 and 8,21 (2m, 2H, naphthalene H), 8,25 (s broad, 1 H, NH), 9,40 (s broad, 1 H, OH). Step iv - preparation of: 4-[(1-methoxy-2-naphthvDamino1benzoic acid (ST3453).
A solution of ST3452 (700 mg, 2,3 mmol) and 1N NaOH (5,75 ml) in THF/ethanol 1 :1 was refluxed for 1 h and 40min under stirring. Then the mixture was poured onto crushed ice and extracted with ethyl acetate (1 x 20 ml). The aqueous layer was treated with 1 N HCI and then extracted with ethyl acetate (3 x 100 ml). The organic extracts were collected, washed with brine (3 x 100 ml), dried and the solvent was removed to yield ST3453 (700 mg,100%); p.f. 233-235 0C (EtOH); IR: v 3403 (COOH e NH), 1691 (CO) cmJ; 1H-NMR (DMSO-d6): δ 3,80 (s, 3H, CH3), 7,01 (d, 2H, J0 = 8,6 Hz, benzene C2-H and C6-H), 7,46-7,59 (m, 1H, naphthalene H), 7,72 (m, 1 H, naphthalene H), 7,82 (d, 2H, J0 = 8,6 Hz, benzene C3-H and C5-H 7,64-7,69), 7,93 and 8,08 (2m, 2H, naphthalene H), 8,59 (s broad, 1 H, NH), 12,32 (s broad, 1 H, COOH). Example 3 - Preparation of compounds of Formula (I) according to synthetic Scheme 3
Figure imgf000040_0001
ST2763 ST2764
Reagents and conditions: i) Methyl 4-Br-benzoate Cs2CO3 Pd(OAc)2 (±) BINAP toluene, 800C
16 h; ii) 1N NaOH, THF/ethanol 1 :1 , reflux 3 h. Step /' - Preparation of methyl 4-(1-naphthylamino)benzoate (ST2763)
A dried flask was purged with argon and charged with (±) BINAP (70 mg, 0.11 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (9.7 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved (~1 min). The solution was cooled to room temperature, the septum was removed, and palladium acetate (16 mg, 0.07 mmol) was added. The flask was recapped with the septum and then purged with argon (for -30 sec). The mixture was stirred at room temperature for 1 min, the 1-naphthalenylamine (600 mg, 3.5 mmol) dissolved in toluene (1.5 ml) and methyl-4-bromobenzoate (623 mg, 2,9 mmol) were added, the septum was removed, and cesium carbonate (1.31 g, 4.0 mmol) was added. Additional toluene (7 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 8O0C with stirring for 16 h. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product was then purified by column chromatography (chloroform/petroleum ether 3:1 as eluent) to obtain 771 mg (96%) of pure ST2763. mp 130-132 0C (toluene); IR: v 3340 (NH), 1694 (CO) cm-1 ; 1H-NMR (DMSO-cfe): δ 3.79 (s, 3H, CH3), 6.95 (m, 2H, benzene C3-H and C5-H), 7.45-7.60 (m, 4H, naphthalene H), 7.73 (m, 1H, naphthalene H), 7.79 (m, 2H, benzene C2-H and C6-H), 7.98 (m, 1 H, naphthalene H), 8.06 (m, 1 H, naphthalene H), 8.88 (s broad, 1 H, NH).
Step H - 4-(1-naphthylamino)benzoic acid (ST2764)
A solution of ST2763 (415 mg, 1.5 mmol) and 1N NaOH (3.7 ml) in THF/ethanol 1 :1 (20 ml) was refluxed for 3 h while stirring. Then the mixture was poured onto crushed ice and extracted with ethyl acetate (30 ml). The aqueous layer was treated with 1 N HCI until pH 3 and then extracted with ethyl acetate (3 x 50 ml). The organic extracts were collected, washed with brine (3 x 100 ml), dried and the solvent was removed to yield ST2764 232 mg,( 59%). mp 227-229 0C (toluene); IR: v 3390 (NH), 2900 (OH), 1670 (CO) cm"1 ; 1H-NMR (DMSO-c/6): δ 6.95 (m, 2H, benzene C3-H and C5-H), 7.46-7.60 (m, 4H, naphthalene H), 7.72 (m, 1 H, naphthalene H), 7.78 (m, 2H, benzene C2-H and C6-H), 7.96 (m, 1 H, naphthalene H), 8.07 (m, 1H, naphthalene H), 8.81 (s broad, 1 H, NH), 12.29 (s broad, 1 H, OH).
Example 4 - Preparation of compounds of Formula (I) according to synthetic Scheme 4
Scheme 4
Figure imgf000043_0001
ST2760
111
Figure imgf000043_0002
ST2757 ST2759
Reagents and conditions: i) H2 60 psi, 10% Pd/C ethyl acetate, rt 4h; ii) methyl 2-Br-benzoate Cs2CO3 Pd(OAc)2 (±) BINAP toluene, 8O0C 15.5 h; iii) BBr3 CH2CI2 -45°C 19.5 h then rt. 23 min. iv) 2-methoxy-1-bromo-naphtalene, Cs2CO3 Pd(OAc)2 (±) BINAP toluene, 800C;
Step /- Preparation of 2-methoxy-i-naphthalenamine.
2-Methoxy-1-naphthalenamine was obtained with the same procedure reported above, (step /,scheme1 ) using 2-methoxy-1-nitronaphthalene (3.00 g, 14.8 mmol) as starting material. The 2-methoxy-1-naphthylenamine (2.6 g, 100 %) obtained was used for the next reaction without further purification.
Step /'/' - Preparation of methyl-2-(2-methoxy-1-naphthalenylamino)benzoate (ST2760). A dried flask was purged with argon and charged with (±) BINAP (70 mg,
0.11 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (9.7 ml) was added. The mixture was heated to 80 °C with stirring until the BINAP dissolved (~1 min). The solution was cooled to room temperature, the septum was removed, and palladium acetate (16 mg, 0.07 mmol) was added. The flask was recapped with the septum and then purged with argon (for ~30 sec). The mixture was stirred at room temperature for 1 min, the 2-methoxy-1- naphthalenylamine (606 mg, 3.5 mmol) dissolved in toluene (1.5 ml) and methyl-2- bromobenzoate (615 mg, 2,9 mmol) were added, the septum was removed, and cesium carbonate (1.31 g, 4.0 mmol) was added. Additional toluene (7 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 8O0C with stirring for 15.5 h . The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo;the crude product was purified by column cromatogrphy ethyl acetate//?-hexane 1 :5,to obtain ST2760 890mg 100 %; mp 144-146 0C (cyclohexane); IR: v 3321 (NH), 1681 (CO) cm"1 ; 1H-NMR (DMSO-d6): δ 3.86 (s, 3H, CH3), 3.89 (s, 3H, CH3), 6.09 (m, 1H, benzene H), 6.66 (m, 1H, benzene H), 7.18 (m, 1 H, naphthalene H), 7.35- 7.45 (m, 2H, benzene H and naphthalene H), 7.57 (m, 1 H, naphthalene H), 7.68 (m, 1 H, benzene H), 7.88-7.95 (m, 3H, naphthalene H), 9.17 (s broad, 1 H, NH). Step Hi - Preparation of methyl 2-r(2-hvdroxy-1-naphthv0amino1benzoate (ST2759) and 2-IY2-hvdroxy-1-naphthv0aminolbenzoic acid (ST2757)
A solution of ST2760 (736 mg, 2.4 mmol) in dichloromethane (27 ml) was added dropwise to 1M BBr3 (12.6 ml, 12.6 mmol) in the same solvent at -45°C, under argon atmosphere. The mixture was stirred for 19,5 h at the same temperature, and then warmed at room temperature and stirred for 23 min; then treated with water (50 ml). The mixture was extracted with ethyl ether (3 x 50 ml) and the organic extracts were collected, washed with brine (3 x 100 ml) and dried. Evaporation of the solvent gave a crude product, which was chromatographed (ethyl acetate/n-hexane 1 :2 as eluent) ; first eluates ST2759, 316mg ,45%; mp 157-158 0C (cyclohexane); IR: v 3407 (OH), 3319 (NH), 1681 (CO) crrr1; 19.5 h; 1 H-NMR (DMSO-d6): δ 3.88 (s, 3H, CH3), 6.10 (m, 1H, benzene H), 6.64 (m, 1 H, benzene H), 7.17 (m, 1 H, naphthalene H), 7.28-7.31 (m, 2H, naphthalene H), 7.39 (m, 1 H, benzene H), 7.62 (m, 1H, benzene H), 7.77 (m, 1 H, naphthalene H), 7.84- 7.95 (m, 2H, naphthalene H), 9.05 (s broad, 1 H, NH), 9.78 (s broad, 1H, OH). Further elution afforded ST2757.368 mg 55%; mp 215-216 0C (toluene); IR: v 3361 (OH, COOH), 3325 (NH), 1659 (CO) cm"1 ; 1 H-NMR (DMSO-d6): δ 6.09 (m, 1 H, benzene H), 6.62 (m, 1 H, benzene H), 7.14 (m, 1H, naphthalene H), 7.28-7.31 (m, 2H, naphthalene H), 7.39 (m, 1 H, benzene H), 7.62 (m, 1 H, benzene H), 7.75 (m, 1 H, naphthalene H), 7.83-7.89 (m, 2H, naphthalene H), 9.28 (s broad, 1 H, NH), 9.76 (s broad, 1 H, OH), 12.86 (s broad, 1 H, COOH).
Step /V - Preparation of 2-methoxy-N-(2-methoxy-1-naphthvDnaphthalen-1- amine (ST2761) A dried flask was purged with argon and charged with (±) BINAP (200 mg,
0,323 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (29 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved (~1 min). The solution was cooled to room temperature, the septum was removed, and palladium acetate (50 mg, 0,218 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, the 2-methoxynaphthalen-1-yl-amine (1 ,81 g, 10,5 mmol) dissolved in toluene (4,5 ml) and 2-methoxy-1- bromonaphthalene (2,07 g, 8,73 mmol) were added, the septum was removed, and cesium carbonate (3,98 g, 12,2 mmol) was added. Additional toluene (21 ,2 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 8O0C with stirring for 2Oh. The (±) BINAP (200 mg, 0,323 mmol), palladium acetate (50 mg, 0,218 mmol) and toluene (29 ml) were added. The mixture was heated to 8O0C with stirring for 15h. The (±) BINAP (200 mg, 0,323 mmol), palladium acetate (50 mg, 0,218 mmol) and toluene (29 ml) were added. The mixture was heated to 8O0C with stirring for 24h . The (±) BlNAP (200 mg, 0,323 mmol), palladium acetate (50 mg, 0,218 mmol) and toluene (29 ml) were added The mixture was heated to 800C with stirring for 2Oh . The mixture was cooled at room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (5,03 g) was then purified by column chromatography (ethyl acetate/n-hexane 1 :5 as eluent) to obtain 1 ,69 g (59 %) of pure ST2761 (Oil). IR: v 3380 (NH), cm"1 ; 1H-NMR (DMSO-Of6): δ 3,55 (s, 6H, CH3), 7,05 (s broad, 1 H, NH), 7,20-7,38 (m, 6H, naphthalene H), 7,58 (m, 2H, naphthalene H), 7,81-7,93 (m, 4H, naphthalene H).
Example 5 - Preparation of compounds of Formula (I) according to synthetic
Scheme 5
Figure imgf000048_0001
Reagents and conditions: i) DPEphos,Pd2dba3, toluene,t-Buok,100°C, argon
Figure imgf000048_0002
ii) BBr3 CH2Cl2 -450C 15 h then rt 6,45 h; iii) MeOH, oxone, O0C then rt 16 h; ST3500 iv) BBr3 CH2Cl2 -45°C 20 min. then rt 2Oh Step i - preparation of:
1-methoxy-4-r(4-methoxyphenyl)thiolnaphthalene(ST3498). A dried flask was charged with Pd2dba3 (130 mg, 0,141 mmol) dissolved in degassed toluene (1 15 ml), treated with DPEphos (150 mg, 0,282 mmol) and purged with argon. The mixture was stirred at room temperature for 3 min, then 1- methoxy-4-iodonaphthalene (4 g, 14,1 mmol) and 4-methoxythiophenol (2,02 g, 14,1 mmol, 1.77 ml) were added under argon atmosphere. M3uOK (1 ,74 g, 15,5 mmol) was added and the flask purged with argon. The mixture was stirred for 2h at 100°C, cooled at room temperature, filtered on celite cake and the filtered was concentrated under vacuo. The crude product (6,19 g) was purified by column chromatography (n-hexane/acetone 10:1 as eluent) obtaining the unclear final product (3.57g), which was further purified by crystallization (n-hexane) obtaining 2,70 g (65%) of pure ST3498. p.f. 83-85 0C (n-hexane); IR: v 2937 (CH) cm"1; 1H- NMR (acetone-d6): δ 3,78 (s, 3H, CH3), 4,10 (s, 3H, CH3), 6,88 (d, 2H, J0 = 8,86 Hz, benzene H), 7,03 (d, 1 H, J0 = 8,01 Hz, naphthalene C2-H), 7,20 (d, 2H, J0 = 8,86 Hz, benzene H), 7,57-7,64 (m, 2H, naphthalene C6-H and C7-H), 7,75 (d, 1 H, J0 = 8,01 Hz, naphthalene C3-H), 8,34 and 8,40 (2m, 2H, naphthalene C5-H and C8-H). Step Hi - preparation of: 1-methoxy-4-r(4-methoxyphenyl) sulfonylinaphthalene (ST3499).
ST3498 (1 g, 3,4 mmol) was dissolved in MeOH (84 ml). At 00C a solution of oxone® (6,27 g, 10,2 mmol) in water (20 ml) was added. The mixture was stirred for 16h at room temperature. The mixture was poured in water, extracted with ethyl acetate (3 x 100 ml), the collected organic layers washed with brine (3 x 100 ml) and dried over Na2SO4 anhydrous. The solvent was evaporated in vacuo obtaining a crude product which was purified by column chromatography (chloroform as eluent) affording the pure product ST3499 (82%); p.f. 165-167°C (toluene). IR: v 2900 (CH) cm"1; 1H-NMR (DMSO-c/6): δ 3,82 (s, 3H, CH3), 4,12 (s, 3H, CH3), 7,11 (d, 2H, J0 = 8,69 Hz, benzene H), 7,25 (d, 1 H, J0 = 8,47 Hz, naphthalene C2-H), 7,64 and 7,72 (2m, 2H, naphthalene C6-H and C7-H), 7,90 (d, 2H, J0 = 8,69 Hz, benzene H), 8,30 (d, 1 H, J0 = 8,47 Hz, naphthalene C3-H), 8,46 and 8,52 (2m, 2H, naphthalene C5-H and C8-H). Step iv - preparation of: 4-IY4-hvdroχyphenvPsulfonvπ-1 -naphthol (ST35001
A solution of 1-methoxy-4-[(4-methoxyphenyl)sulphonyl]-naphthalene (ST3499) (1g, 3 mmol) in dichloromethane (35 ml) was added dropwise to 1M BBr3 dichlorometane solution (15,9 ml, 15,9 mmol) at -45°C, under argon atmosphere. The mixture was stirred for 20 min at the same temperature and 2Oh at room temperature. The mixture was diluted with water (100 ml) and extracted with ethyl acetate (3 x 100 ml); the organic layers were collected, washed with brine (3 x 100 ml), dried and evaporated under vacuo obtaining a crude product (900 mg), which was purified by column chromatography (ethyl acetate/chloroform 1 :2 as eluent) to afford 520 mg of pure ST3500 (58%); p.f. 203-2050C (toluene). IR: v 3300 (OH) cm"1; 1H-NMR (DMSO-cfe): δ 6,90 (d, 2H, J0 = 8,77 Hz, benzene H), 7,07 (d, 1 H, J0 = 8,29 Hz, naphthalene C2-H), 7,58 and 7,67 (2m, 2H, naphthalene C6-H and C7-H), 7,77 (d, 2H, J0 = 8,77 Hz, benzene H), 8,28-8,31 (m, 2H, naphthalene C5-H and C8-H), 8,48 (d, 1 H, J0 = 8,29 Hz, naphthalene C3- H), 10,54 and 11 ,51 (2s broad, 2H, OH). Step ii - preparation of: 4-r(4-hvdroχyphenvnthiol-1 -naphthol (ST3501 ).
A solution of 1-methoxy-4-[(4-methoxyphenyl)thio]-naphthalene ST3498 (800 mg, 2,7 mmol) in dichloromethane (33 ml) was added dropwise to 1M BBr3 Dichlorometane solution (14,1 ml, 14,1 mmol) at -450C, under argon atmosphere. The mixture was stirred for 15 h and 35min at the same temperature and 6h and 45min at room temperature. The mixture was diluted with water (100 ml) and extracted with ethyl acetate (3 x 100 ml); the organic layers were collected, washed with brine (3 x 100 ml), dried and evaporated under vacuo obtaining a crude product, which was purified by column chromatography (ethyl acetate/n- hexane 2:5 as eluent) to afford 440 mg of pure ST3501 (61%); p.f. 161-163°C (toluene). IR: v 3255 (OH) cm"1; 1H-NMR (DMSO-d6): δ 6,70 (d, 2H, J0 = 8,69 Hz, benzene H), 6,93 (d, 1H, J0 = 7,89 Hz, naphthalene C2-H), 7,06 (d, 2H, J0 = 8,69 Hz, benzene H), 7,51-7,62 (m, 3H, C3-H, naphthalene C6-H and C7-H), 8,23 and 8,27 (2m, 2H, naphthalene C5-H and C8-H), 9,52 and 10,61 (2s broad, 2H, OH).
Example 6 - Preparation of compounds of Formula (I) according to synthetic Scheme 6
Scheme 6
Figure imgf000052_0001
R = F, R1 = F ST3598 =ST3450 (HCl)
R = N(CH3)2, R1 = SCH3 ST3458 (HCl) =ST3718
R = F, R1 = SCH3 ST3455
Reagents and conditions: i) Cs2CO35Pd (OAc)2 (±) BINAP toluene, 800C;
Step i - preparation of: 4-fluoro-N-(4-fluorophenvπnaphthalen-1 -amine ( ST35981
A dried flask was purged with argon and charged with (±) BINAP (160 mg, 0,25 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (24 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved. The solution was cooled to room temperature, the septum was removed, and palladium acetate (40 mg, 0,17 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, the 4-fluoroaniline (890 mg, 8.04 mmol) dissolved in toluene (3 ml) and 1-bromo-4-fluoronaphthalene (1 ,50 g, 6,7 mmol) were added, the septum was removed, and cesium carbonate (3,06 g, 9,38 mmol) was added. Additional toluene (18 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 800C under stirring for 5h and 45 min. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (2,31 g) was then purified by column chromatography (Chloroform as eluent) to obtain 1.87 g (91%) of pure ST3598. p.f. 62-64 0C (not crystallized); IR: v 3395 cmJ (NH); 1H- NMR (CDCI3): δ 5,55 (s broad, 1 H, NH), 6,86-6,90 (m, 2H, benzene H), 6,98-7,03 (m, 2H, benzene H), 7,11-7,17 (m, 1H, naphthalene C2-H), 7,24 (m, 1H, naphthalene C3-H), 7,57-7,66 (m, 2H, naphthalene C6-H and C7-H), 8,05 and 8,20 (2m, 2H, naphthalene C5-H and C8-H).
4-fluoro-N-(4-fluorophenvDnaphthalen-1 -amine hydrochloride (ST3450).
Acetyl chloride (310 mg, 3,9 mmol) was carefully added in methanol (17 ml) cooled at 0 0C, under argon stream. A solution of ST3598 (1 ,00 g, 3,9 mmol) in methanol (1 ml) was added dropwise to the hydrochloric solution gently stirred. After 15 min under stirring at the same temperature, the solution was concentrated and cooled at -18°C for 5 days to give ST3450 (100 %); p.f. 63-65°C; IR: v 3390 (NH) cm-1 ; 1H-NMR (CDCI3): δ 5,55 (s broad, 1H, NH), 6,88-6,92 (m, 2H, benzene H), 6,99-7,03 (m, 2H, benzene H), 7,11-7,16 (m, 1 H, naphthalene C2-H), 7,23-7,26 (m, 1 H, naphthalene C3-H), 7,58-7,66 (m, 2H, naphthalene C6-H and C7-H), 8,06 and 8,20 (2m, 2H, naphthalene C5-H and C8-H). N.N-dimethyl-N'-[4-(methylthio)phenyllnaphthalene (ST3718).
A dried flask was purged with argon and charged with (±) BINAP (140 mg, 0,22 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (21 ml) was added. The mixture was heated to 80 0C with stirring until the BINAP dissolved. The solution was cooled to room temperature, the septum was removed, and palladium acetate (33 mg, 0,147 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, the 4-(methylthio)aniline (990 mg, 7.08 mmol) dissolved in toluene (1 ml) and 1-bromo-4-(dimethylamino)naphthalene (1 ,47g, 5,9 mmol) dissolved in toluene (1 ml) were added, the septum was removed, and cesium carbonate (2,69 g, 8,26 mmol) was added. Additional toluene (16 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 800C under stirring for 16h. A solution of (±) BINAP (140 mg, 0,22 mmol) and palladium acetate (33 mg, 0,147 mmol) dissolved in toluene (21ml) was added and the mixture was stirred at 800C for 4h and 50min. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (2,87 g) was then purified by column chromatography (Chloroform as eluent) to obtain 1 ,48 g (81%) of pure ST3718. Oil; IR: v 3381 (NH) cmJ; 1H-NMR (DMSO-d6): δ 2,42 (s, 3H, SCH3), 2,84 (s, 6H, NCH3), 6,86 (d, 2H, J0 = 8,8 Hz, benzene C2-H and C6-H), 7,14-7,20 (m, 3H, naphthalene H and benzene C3-H and C5-H), 7-7,56 (m, 2H, naphthalene C2-H and C3-H), 8.07-8.09 (m, 2H, NH and naphthalene H), 8,23 (m, 1 H, naphthalene H). N,N-dimethyl-N'-r4-(methylthio)phenyllnaphthalene-1 ,4-diamine dihvdrochloridedichloridrate (ST3458).
Acetyl chloride (410 mg, 5,2 mmol) was carefully added in methanol (1 ml) cooled at 0 0C, under argon stream. A solution of ST3718 (800 mg, 2,6 mmol) in methanol (4 ml) was added dropwise to the hydrochloric solution gently stirred. The solution was stirred for 15 min at 00C, diluted with ethyl ether and further stirred for 10 min at 00C. The precipitate was filtered obtaining ST3458 (88%); p.f. 204-205°C (isopropyl alcohol); IR: v 3278 (NH) cm"1 ; 1H-NMR (DMSOd6): δ 2,46 (S, 3H, SCH3), 3,19 (s, 6H, NCH3), 4,13 (s broad, 2H, NH), 7,07-7,09 (d, 2H, J0 = 8,8 Hz, benzene C2-H and C6-H), 7,25-7,27 (m, 3H, naphthalene C3-H and benzene C3-H and C5-H), 7,62-7,73 (m, 3H, naphthalene C2-H, C7-H and C8-H), 8.31-8.45 (m, 3H, naphthalene C5-H, C8-H and NH). 4-fluoro-N-[4-(methylthio)phenvπnaphthalen-1 -amine (ST3455).
A dried flask was purged with argon and charged with (±) BINAP (160 mg, 0,25 mmol) and capped with a rubber septum. The flask was purged with argon and toluene (24 ml) was added. The mixture was heated to 80 °C with stirring until the BINAP dissolved. The solution was cooled to room temperature, the septum was removed, and palladium acetate (40 mg, 0,17 mmol) was added. The flask was recapped with the septum and then purged with argon. The mixture was stirred at room temperature for 1 min, the 4-(methylthio)aniline (1 ,12 g, 8.04 mmol) dissolved in toluene (3 ml) and 1-bromo-4-fluoronaphthalene (1,50 g, 6,7 mmol) were added, the septum was removed, and cesium carbonate (3,06 g, 9,38 mmol) was added. Additional toluene (18 ml) was added, then the flask was recapped with the septum, and purged with argon again. The mixture was heated to 80°C under stirring for 17h. The mixture was cooled to room temperature, diluted with ether, filtered, and concentrated in vacuo. The crude product (2,85 g) was then purified by column chromatography (chloroform/petroleum ether 1 :1 as eluent) to obtain 1 ,79 g (94%) of pure ST3455; p.f. 71-72 0C (n-hexane); IR: v 3337 (NH) cm"1; 1H-NMR (DMSOd6): δ 2,44 (s, 3H, CH3), 6,93 (d, 2H, J0 = 8,7 Hz, benzene C3-H and C5-H), 7,20-7,33 (m, 4H, benzene C2-H and C3-H, naphthalene C2-H and C3-H), 7,63-7,71 (m, 2H, naphthalene C6-H and C7-H), 8,07 and 8,18 (2m,
2H, naphthalene C5-H and C8-H), 8,21 (s broad, 1 H1NH).
Example 7 - General analytical methods Melting points were determined on a Bibby Stuart Scientific SMP1 melting point apparatus and are uncorrected.
Infrared (IR) spectra (Nujol mulls) were recorded on a Perkin-Elmer
Spectrum-one spectrophotometer.
1H NMR spectra were recorded at 400 MHz on a Bruker AC 400 Ultrashield spectrophotometer (400 MHz). Dimethylsulfoxide-c/6 99.9% (code 44,139-2) and deuterochloroform 98.8% (code 41 ,675-4) of isotopic purity (Aldrich) were used. The solvent Column chromatographies were performed on silica gel (Merck;
70-230 mesh) column. All compounds were routinely checked by TLC by using aluminium-baked silica gel plates (Fluka DC-Alufolien Kieselgel 60 F2S4). Developed plates were visualized by UV light. Solvents were reagent grade and, when necessary, were purified and dried by standard methods. Concentration of solutions after reactions and extractions involved the use of rotary evaporator
(Bϋchi) operating at a reduced pressure (ca. 20 Torr). Organic solutions were dried over anhydrous sodium sulfate (Merck). Example 8 - Evaluation of anti-aqgreqatinq activity of the compounds of formula (\) on the peptide βAmyloid i-4?.
The anti-aggregating activity of the compound of formula (I) on the peptide βA-i-42 is carried out via the binding of the thioflavin T according to the following procedure.
Preparation of the non aggregate B-An-4?^
The β-A(i-42) was dissolved in a mixture of Acetonitrile and distilled water (CH3CN/H2O 1 :1 ) to the final concentration of 1 mg/mL The solution was divided in aliquots of 2 ml_ and stored at -8O0C until the use. The work solution was prepared diluting the stock solution five times with H2O (final concentration 44.μmol/L).
Preparation of the aggregate B-An-4?^
The β-A(i-42) was dissolved in a mixture of Acetonitrile and distilled water (CH3CN/H2O 1 :1 ) to the final concentration of 1 mg/mL. An aliquot of 2 ml_ was freeze-dried to eliminate the trifluoroacetic acid residual of the peptide synthesis. The β-A(i-42) peptide was subsequently dissolved in 0.1 ml_ of DMSO and 5.0 ml_ of 2xPBS, pH 7.4. Once dissolved the β-A(1-42) was incubated to 37°C for 8 days, at the end, after sonication, it was diluted five times with 2xPBS (final concentration 17.4 μmol/L). Waiting to be used, the aggregate β-A(i-42) was divided in aliquots and stored at -8O0C. Fluorescence measurement with thioflavin T
Scheme of added volumes in 96-well plates:
Figure imgf000058_0001
The assay was performed in triplicate in 96-well plates as reported above in scheme. Test compounds were added in the wells containing the aggregate β-A(i_ 42) then, 15 after minutes, the non-aggregate β-A(i-42) was added. The 96-well plates were incubated at 37°C under agitation for 24 hours. The following day, a volume of 200 μl_ of a solution containing 10 μmol/L thioflavin T and 50 μmol/L Na2HPO4 pH 6.5 was added to each well. Fluorescence was measured in a VICTOR 2 (WALLAC) fluorescence spectrophotometer (λex=450 nm, λem=486 nm) (Findelis M.A et al). Calculations and tables were elaborated by means of a PC. The data were expressed as percent of residual aggregated β-A and, when possible, the dose reducing the aggregate formation of the 50% (IC50) was estimate.
The % of aggregation was determinated by the following formula: (βAmyloid+Test compound) - ( Blank+Test compound) x 100 (Control+βAmyloid) - Blank Results
Table A shows the IC50 of the compounds. The results on compound ST1859 (1- [(2-hydroxy-1-naphthyl)methyl]-2-naphthol) (see WO02/00603) have been reported for comparative purposes.
Table A
Figure imgf000059_0001
Example 9 - Blood brain barrier crossing
In order to obtain basic information on the concentration achieved in brain of rodents after parental doses and their relationship with plasma concentrations, mice and rats were used. Animals were divided into groups and received compound subcutaneously or intravenously and were killed by decapitation 0, 15, 30, 60, 120, 180 and 240 min after dosing to determine plasma and brain concentrations of compounds. Compounds were determined in plasma by high- performance liquid chromatography (HPLC) after a solid liquid extraction procedure. Briefly, Oasis HLB 1cc cartridges were pre-wetted with methanol and distilled water. Then internal standard, mouse plasma or rat plasma were added and the cartridges were washed with mater-methanoland methanol, interrupting the vacuum before the column was completely dry after each passage. The compound was removed by eluiting the cartridges with methanol and evaporated to dryness under nitrogen. The residue was dissolved in the mobile phase centrifuged and analyzed by HPLC with UV detection (224 nm). Separation was done on a μBondapack C18 column protected by a LiChrosphere RP-8 pre-column at room temperature. The mobile phase was CH3CN:CH3OH:0.001M KH2PO4 (40:10:50 v/v) delivered at a flow rate of 1.2 mL/min.
Brain tissue was homogenized (1g/10ml) in CH3CN:0.001M phosphate buffer, pH 7.4 and a volume containing approximately 100 mg of tissue was centrifuged. The supernatant was processed as for plasma.
Mean brain and plasma area under the concentration-time curve (AUCt) were determined using the linear trapezoidal rule and extrapolated to infinity (AUC) by the concentration method. The elimination rate constant was calculated by least squares regression analysis of the terminal log-linear portion of the plasma and the brain drug concentration curves. The maximum concentration (Cmax) and the time (tmax) of its occurrence were read directly from the plasma and brain concentration time data. Results
Table B show the plasma and brain concentration-time curves of compound ST2175 after s.c. injection (25 mg/kg) in mice.
Table B
Figure imgf000061_0001
Table C shows the plasma and brain AUC of compound ST2175 after s.c. injection (25 mg/kg) in mice.
Table C
Figure imgf000061_0002

Claims

CLAIMS 1. Use of a compound of Formula (I) as a medicine
Figure imgf000062_0001
(I) where:
R is selected from the group consisting of H, OR3, COOR3, N(R3)2, NO2, halogen, hydroxyalkyl Ci-C3;
Ri and R2 are the same or different and are selected from the group consisting of H; OR3; COOR3; linear or branched, saturated or unsaturated C1-C4 alkyl;
N(R3)2; C1-C4 linear or branched, saturated or unsaturated alkylthio; halogen; and
SO2N(Rs)2;
R3 is selected from the group consisting of H; C1-C4 linear or branched alkyl;
PO3H2, and PO3(CH3)2; A is selected from the group consisting of NR4; S; and SO2;
R4 is selected from the group consisting of H; C1-C4 linear or branched alkyl; Ci-
C4 linear or branched alkanoyl; and
B is a phenyl or naphthyl group.
2. The use according to claim 1 , wherein A is NH.
3. The use according to claims 1 or 2, wherein Ri is H .
4. The use according to any preceding claim, wherein R2 is selected from the group consisting of H, COOH, COOCH3 and OH.
5. The use according to any preceding claim, wherein R is selected from the group consisting of H, OH and OCH3.
6. The use according to any preceding claim, wherein the compound of
Formula (I) is selected from the group consisting of:
1 -hydroxy-N-phenylnaphthalen-2-aminium chloride; methyl 4-(1 -naphthylamino)benzoate;
4-(1-naphthylamino)benzoic acid; 4-(4-hydroxyanilino)-1 -naphthol;
4-anilino-1-naphthol;
2-[(2-hydroxy-1 -naphthyl)amino]benzoic acid;
(1-methoxy-2-naphthyl)phenylamine;
4-methoxy-N-phenyl-1-naphthalenamine; 1-methoxy-4-[(4-methoxyphenyl) sulfonyl]naphthalene; and
4-[(4-hydroxyphenyl)sulfonyl]-1 -naphthol.
7. The use according to any preceding claim, for the preparation of a medicine
for the treatment of diseases characterised by deposits of amyloid aggregates.
8. The use according to Claim 7, in which the condition characterised by
deposits of amyloid aggregates is selected from among the group consisting of Alzheimer's disease, Down's syndrome, hereditary cerebral haemorrhage accompanied by "Dutch type" amyloidosis, amyloidosis accompanied by chronic inflammation, amyloidosis accompanied by multiple myeloma and other dyscrasias of the haematic "B" lymphoid cells, amyloidosis accompanied by type Il diabetes, amyloidosis accompanied by prion diseases, kuru or ovine scrapie.
9. The use according to Claim 7, in which amyloidosis accompanied by prion diseases is selected from among the group consisting of Creutzfeldt-Jakob's disease or Gerstmann-Straussler syndrome.
10. A compound of Formula (I)
Figure imgf000064_0001
(I) where: R is selected from the group consisting of H, OR3, COOR3, N(R3)2, NO2, halogen, hydroxyalkyl Ci-C3;
Ri and R2 are the same or different and are selected from the group consisting of
H; OR3; COOR3; linear or branched, saturated or unsaturated C1-C4 alkyl;
N(R3)2; C1-C4 linear or branched, saturated or unsaturated alkylthio; halogen; and SO2N(R3)2; provided that Ri and R2 are not both H or halogen;
R3 is selected from the group consisting of H; C1-C4 linear or branched alkyl;
PO3H2, and PO3(CH3)2; A is selected from the group consisting of NR4; S; and SO2;
R4 is selected from the group consisting of H; Ci-C4 linear or branched alkyl; Ci-
C4 linear or branched alkanoyl; and
B is a phenyl or naphthyl group, with the proviso that: when A is NR4, Ri and R2 are not both OR3; and with the exception of the following compounds:
4-methoxy-N-phenyl-1-naphthalenamine;
1 -hydroxy-N-phenylnaphthalen-2-aminium chloride;
methyl 4-(1-naphthylamino)benzoate;
4-(1-naphthylamino)benzoic acid;
4-(4-hydroxyanilino)-1-naphthol;
4-anilino-1-naphthol;
2-[(2-hydroxy-1 -naphthyl)amino]benzoic acid; (1 -methoxy-2-naphthyl)phenylamine;
1-methoxy-4-[(4-methoxyphenyl) sulfonyl]naphthalene; and
4-[(4-hydroxyphenyl)sulfonyl]-1-naphthol.
11. The compound according to claim 10, wherein A is NH.
12. The compound according to claim 10 , wherein R is selected between OH
and OCH3
13. The compound according to claim 10 , wherein Ri is selected among OCH3,
COOCH3, H and COOH
14. The compound according to claim 10 , wherein R2 is selected among H, I,
OH and OCH3.
15. The compound according to claim 10, which is selected from the group consisting of: methyl 2-[(2-methoxy-1-naphthyl)amino]benzoate;
1-methoxy-4-[(4-methoxyphenyl)thio]naphthalene;
N-(4-iodophenyl)-1-methoxynaphthalen-2-amine;
2-hydroxy-5-[(4-hydroxy-1-naphthyl) amino] benzoic acid;
methyl 2-[(2-hydroxy-1 -naphthyl)amino]benzoate; methyl 4-[(1-hydroxy-2-naphthyl) amino] benzoate ;
4-[(1 -hydroxy-2-naphthyl)amino]benzoic acid;
4-[(1 -methoxy-2-naphthyl)amino]benzoic acid; methyl-4-[(1-methoxy-2-naphthyl) amino] benzoate;
4-[(4-hydroxy-1 -naphthyl)amino]benzoic acid; 4-[(4-hydroxyphenyl)thio]-1-naphthol ;
4-[(4-methoxy-1 -naphthyl)amino]benzoic acid;
N,N-dimethyl-N'-[4-(methylthio)phenyl]naphthalene-1 ,4-diamine dihydrochloride;
4-fluoro-N-(4-fluorophenyl)naphthalen-1 -amine hydrochloride;
4-fluoro-N-[4-(methylthio)phenyl]naphthalen-1 -amine; 2-hydroxy-5-[(4-hydroxy-1-naphthyl)amino]benzoic acid hydrochloride;
4-methoxy-3-methylbenzoate-1 -yl(4-methoxy-1 -naphthyl)amine;
N-(5-iodo-2-methoxyphenyl)-N-(4-methoxy-1-naphthyl)amine;
N-(4-methoxy-1-naphthyl)-N-(2-methoxyphenyl)amine; 2-methoxy-5-[(4-methoxy-1-naphthyl)amino]benzoic acid; 4-methoxy-N-(4-methoxyphenyl)-1-naphthalenamine; 4-methylbenzoate-1 -yl(4-methoxy-1 -naphthyl)amine; N-(4-methoxyphenyl)-4-nitronaphthalen-1 -amine; 2-methoxy-N-(2-methoxy-1-naphthyl)naphthalen-1 -amine; and methyl 4-[(4-hydroxy-1 -naphthyl)amino]benzoate.
16. A compound of any of claims 10 to 15, as a medicament.
17. Use of a compound according to any of claims 10 to 15, for the preparation of a medicine for the treatment of diseases characterised by deposits of amyloid aggregates.
18. A pharmaceutical composition containing as active ingredient a compound of
any of claims 10 to 15, and at least one pharmaceutically acceptable excipient and/or diluent.
19. The pharmaceutical composition according to claim 18 for the treatment
and/or prevention of disorders characterised by deposits of amyloid aggregates.
20. A process for preparing the compounds according to any of claims 10 to 15, comprising hydrogenating substituted or un-substituted nitro-naphthalene with catalyst in an organic solvent; condensating the resulting amine with a substituted
or un-substituted aryl halide derivative in the presence of the reagent BINAP [2,2'- Bis(diphenylphosphino)-1 ,1 '-binaphthyl] and palladium acetate.
21. A process for preparing any of the compositions of previous claims 18 or 19 comprising mixing the compound(s) of any claims from 10 to 15 with suitable excipient(s) and/or diluent(s).
22. Method of treating a mammal suffering from a disorder characterised by deposits of amyloid aggregates, comprising administering a therapeutically effective amount of the compound of any of claims 10 to 15 or any of claims 1 to 6.
23. A compound according to any one of claims 10 to 15 or any of claims 1 to 6, in which at least one of the elements carbon, hydrogen, nitrogen or oxygen are
replaced with a corresponding radioactive isotope.
24. The compound according to claim 23, containing at least one atom of
radioactive iodine.
25. The compound according to claim 23 or 24, complexed with elements used in diagnostic imaging.
26. The compound of according to claim 25, in which the complexed element is selected from the group consisting of indium, gadolinium or technetium.
27. A diagnostic kit, including at least one compound according to any one of
Claims 10 to 26, for the diagnosis of diseases characterised by deposits of amyloid aggregates.
28. Use of the kit of claim 27 for diagnosis by means of the diagnostic imaging technique.
29. The use according to claim 28, in which the said diagnostic imaging technique is selected from among a group consisting of PET, SPECT, NMR or
scanning techniques.
30. The use according to Claim 29, in which the said scanning technique is planar scintigraphy.
PCT/EP2006/067323 2005-10-18 2006-10-12 Naphthyl derivatives as inhibitors of beta-amyloid aggregation WO2007045593A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA200801120A EA200801120A1 (en) 2005-10-18 2006-10-12 NAPHTILE DERIVATIVES AS AN INHIBITORS AGTAINING BETA-AMYLOID
EP06841263A EP1937243A2 (en) 2005-10-18 2006-10-12 Naphthyl derivatives as inhibitors of beta-amyloid aggregation
AU2006303301A AU2006303301A1 (en) 2005-10-18 2006-10-12 Naphthyl derivatives as inhibitors of beta-amyloid aggregation
JP2008536020A JP2009514810A (en) 2005-10-18 2006-10-12 Naphthyl derivatives as beta amyloid aggregation inhibitors
BRPI0617423-0A BRPI0617423A2 (en) 2005-10-18 2006-10-12 naphthyl derivative inhibitors of beta-amyloid aggregation
US12/090,033 US20080255232A1 (en) 2005-10-18 2006-10-12 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation
CA002622545A CA2622545A1 (en) 2005-10-18 2006-10-12 Naphthyl derivatives as inhibitors of beta-amyloid aggregation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05022706.5 2005-10-18
EP05022706 2005-10-18

Publications (2)

Publication Number Publication Date
WO2007045593A2 true WO2007045593A2 (en) 2007-04-26
WO2007045593A3 WO2007045593A3 (en) 2007-12-27

Family

ID=35892644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/067323 WO2007045593A2 (en) 2005-10-18 2006-10-12 Naphthyl derivatives as inhibitors of beta-amyloid aggregation

Country Status (12)

Country Link
US (1) US20080255232A1 (en)
EP (1) EP1937243A2 (en)
JP (1) JP2009514810A (en)
KR (1) KR20080056221A (en)
CN (1) CN101291665A (en)
AR (1) AR056702A1 (en)
AU (1) AU2006303301A1 (en)
BR (1) BRPI0617423A2 (en)
CA (1) CA2622545A1 (en)
EA (1) EA200801120A1 (en)
TW (1) TW200800154A (en)
WO (1) WO2007045593A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080821A2 (en) * 2007-12-21 2009-07-02 Giuliani International Limited Receptor targeting ligands
WO2010118706A2 (en) 2009-04-17 2010-10-21 Centro De Neurociencias De Cuba Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2014131374A1 (en) 2013-02-28 2014-09-04 Centro De Neurociencias De Cuba (Neuronic) Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases
WO2015134357A1 (en) * 2014-03-03 2015-09-11 Emory University Modulators of insulin receptor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142208A1 (en) * 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
JPWO2020241416A1 (en) * 2019-05-24 2020-12-03
CN113698416B (en) * 2021-08-25 2022-07-15 大连理工大学 Singlet oxygen carrier for inhibiting beta-amyloid protein aggregation and preparation method and application thereof
CN115894269A (en) * 2022-09-19 2023-04-04 河南师范大学 Biological synthesis method of diarylamine compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059878A2 (en) * 1999-04-02 2000-10-12 Icos Corporation INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
WO2001028546A1 (en) * 1999-10-18 2001-04-26 Universidade Federal Do Rio De Janeiro Inhibition of amyloidoses by using aromatic or heteroaromatic compounds substituted by electron-withdrawing groups
WO2002000603A1 (en) * 2000-06-23 2002-01-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
US20040053890A1 (en) * 2000-11-24 2004-03-18 Brain Christopher Thomas Naphthalene derivatives
US20040132769A1 (en) * 2002-11-26 2004-07-08 Fujimoto Roger A. Certain phenylacetic acids and derivatives
US20040229869A1 (en) * 2003-03-31 2004-11-18 Council Of Scientific And Industrial Research Novel mercaptophenyl naphthyl methane compounds and synthesis thereof
US20050119225A1 (en) * 2002-07-19 2005-06-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059878A2 (en) * 1999-04-02 2000-10-12 Icos Corporation INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
WO2001028546A1 (en) * 1999-10-18 2001-04-26 Universidade Federal Do Rio De Janeiro Inhibition of amyloidoses by using aromatic or heteroaromatic compounds substituted by electron-withdrawing groups
WO2002000603A1 (en) * 2000-06-23 2002-01-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
US20040053890A1 (en) * 2000-11-24 2004-03-18 Brain Christopher Thomas Naphthalene derivatives
US20050119225A1 (en) * 2002-07-19 2005-06-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
US20040132769A1 (en) * 2002-11-26 2004-07-08 Fujimoto Roger A. Certain phenylacetic acids and derivatives
US20040229869A1 (en) * 2003-03-31 2004-11-18 Council Of Scientific And Industrial Research Novel mercaptophenyl naphthyl methane compounds and synthesis thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FINDEIS M A: "BETA-AMYLOID AGGREGATION INHIBITORS" CURRENT OPINION IN CPNS INVESTIGATIONAL DRUGS, PHARMA PRESS, LONDON,, GB, vol. 1, no. 3, 1999, pages 333-339, XP000933869 ISSN: 1464-844X *
MOOSMANN B ET AL: "Protective activity of aromatic amines and imines against oxidative nerve cell death." BIOLOGICAL CHEMISTRY. NOV 2001, vol. 382, no. 11, November 2001 (2001-11), pages 1601-1612, XP009062916 ISSN: 1431-6730 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080821A2 (en) * 2007-12-21 2009-07-02 Giuliani International Limited Receptor targeting ligands
WO2009080821A3 (en) * 2007-12-21 2010-01-14 Giuliani International Limited Multitarget compounds active at a ppar and cannabinoid receptor
JP2011506581A (en) * 2007-12-21 2011-03-03 ジュリアーニ インターナショナル リミテッド Multi-target compounds active at PPAR and cannabinoid receptors
WO2010118706A2 (en) 2009-04-17 2010-10-21 Centro De Neurociencias De Cuba Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease
WO2010118706A3 (en) * 2009-04-17 2010-12-02 Centro De Neurociencias De Cuba Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease
EP2436666A2 (en) * 2009-04-17 2012-04-04 Centro De Neurociencias De Cuba Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of alzheimer 's disease
EP2436666A4 (en) * 2009-04-17 2013-02-13 Ct De Neurociencias De Cuba Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of alzheimer 's disease
EP2860169A2 (en) 2009-04-17 2015-04-15 Centro De Neurociencias De Cuba Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of Alzheimer's disease
EP2860169A3 (en) * 2009-04-17 2015-10-21 Centro De Neurociencias De Cuba Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of Alzheimer's disease
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2014131374A1 (en) 2013-02-28 2014-09-04 Centro De Neurociencias De Cuba (Neuronic) Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases
WO2015134357A1 (en) * 2014-03-03 2015-09-11 Emory University Modulators of insulin receptor

Also Published As

Publication number Publication date
AR056702A1 (en) 2007-10-17
JP2009514810A (en) 2009-04-09
TW200800154A (en) 2008-01-01
CN101291665A (en) 2008-10-22
EA200801120A1 (en) 2008-08-29
CA2622545A1 (en) 2007-04-26
AU2006303301A1 (en) 2007-04-26
BRPI0617423A2 (en) 2011-07-26
US20080255232A1 (en) 2008-10-16
EP1937243A2 (en) 2008-07-02
WO2007045593A3 (en) 2007-12-27
KR20080056221A (en) 2008-06-20

Similar Documents

Publication Publication Date Title
WO2007045593A2 (en) Naphthyl derivatives as inhibitors of beta-amyloid aggregation
CZ20014366A3 (en) Inhibition method of amyloid protein aggregation and representation of amyloid deposits by making use of isoindoline derivatives
CN111936139B (en) Mono (acid) salts of 6-aminoisoquinolines and use thereof
US20080293812A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
RU99115746A (en) NEW CONNECTIONS WITH AN ANALYZING EFFECT
BR112021006843A2 (en) benzoxazole and related compounds useful as modulators of chaperone-mediated autophagy
CN111712265A (en) Diagnostic composition for PET imaging, method for the preparation thereof and use thereof in diagnostics
DE69201141T2 (en) NMDA antagonists.
EP4228655A1 (en) Tetracycline derivatives for treating neurodegenerative or neuroinflammatory diseases
CA2143000C (en) Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
JP7262141B2 (en) Compounds useful as chaperone-mediated autophagy modulators
EP3021944B1 (en) Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
JPH06184152A (en) New compound, its production and brain function improver using the same as main ingredient
JP2023532134A (en) Cyclic compound for use in treating retinal degeneration
BR112020014949B1 (en) METHOD FOR PREPARING AN IMAGE FORMING COMPOUND
JPS62132845A (en) N,n-disubstituted phenylserine derivative and agent for central nervous system containing said compound as active component

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680038767.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1041/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2622545

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006841263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006303301

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12090033

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004968

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008536020

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087009252

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006303301

Country of ref document: AU

Date of ref document: 20061012

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006303301

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200801120

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006841263

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0617423

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080415